



HHS PUBLIC ACCESS

Author manuscript

Sci Transl Med. Author manuscript; available in PMC 2017 January 07.

Published in final edited form as:

Sci Transl Med. 2016 June 01; 8(341): 341ra76. doi:10.1126/scitranslmed.aad3744.

Genomic approach to therapeutic target validation identifies a glucose-lowering *GLP1R* variant protective for coronary heart disease

A full list of authors and affiliations appears at the end of the article.

Abstract

Regulatory authorities have indicated that new drugs to treat type 2 diabetes (T2D) should not be associated with an unacceptable increase in cardiovascular risk. Human genetics may be able to inform development of antidiabetic therapies by predicting cardiovascular and other health endpoints. We therefore investigated the association of variants in 6 genes that encode drug targets for obesity or T2D with a range of metabolic traits in up to 11,806 individuals by targeted exome sequencing, and follow-up in 39,979 individuals by targeted genotyping, with additional *in silico* follow up in consortia. We used these data to first compare associations of variants in genes encoding drug targets with the effects of pharmacological manipulation of those targets in clinical trials. We then tested the association those variants with disease outcomes, including coronary heart disease, to predict cardiovascular safety of these agents. A low-frequency missense variant (Ala316Thr;rs10305492) in the gene encoding glucagon-like peptide-1 receptor (*GLP1R*), the target of GLP1R agonists, was associated with lower fasting glucose and lower T2D risk, consistent with GLP1R agonist therapies. The minor allele was also associated with protection against heart disease, thus providing evidence that GLP1R agonists are not likely to be associated with an unacceptable increase in cardiovascular risk. Our results provide an encouraging signal

*Correspondence can be addressed to: Dawn.M.Waterworth@gsk.com (D. M. W.); robert.scott@mrc-epid.cam.ac.uk (R. A. S.); nick.wareham@mrc-epid.cam.ac.uk (N. J. W.).

†These authors contributed equally to the work

‡Data used in the preparation of this article were obtained from the Genetic and Environmental Risk for Alzheimer's Disease Exome Chip (GERAD_EC) Consortium and Alzheimer's Disease Genetics Consortium (ADGC). As such, the investigators within the GERAD_EC Consortium and ADGC contributed to the design and implementation of GERAD_EC and ADGC and/or provided data but did not participate in analysis or writing of this report.

§Current affiliation: PAREXEL, Durham, NC

Author contributions: RAS, MGE, NJW, DMW conceived and designed the study. RAS, DFF, LL, AYC, PS, RY, NG, AS, YC, TVV, HY, JAL, JHZ, SMW, JW, SW, NM, KM, AP, SJvdL, CG, AAAO, PA, LA, DA, IAO, BB, AB, IB, SBG, JCB, SB, MB, HB, EB, IBB, JBJ, SB, CC, MC, LAC, CC, JC, MdH, JAD, HME, GBE, EF, JF, TF, IF, NGF, FG, CG, SG, LH, JHJ, MEJ, JWJ, RK, FK, NDK, TJK, JK, ZKJ, ATK, KK, JK, AL, CL, GM, KLM, APM, KM, MMN, PBM, CN, SFN, PMN, BGN, CJP, DP, SP, GMP, MP, AP, CJP, JRQ, OR, CS, VS, MJS, NS, SJS, RS, NS, JAS, DJT, ST, RT, DLvdA, YTvdS, JV, MW, KW, JEA, LTA, JLA, ASB, JC, JD, DFE, RAE, JE, PWF, TMF, TH, JMMH, TJ, JK, ML, CL, MIM, JSP, OP, ER, JIR, DS, NJS, HS, PV, SOR, PD, JD, MOG, SK, JBM, MGE, NJW, DMW participated in the acquisition and/or analysis of data. LL, PS, JAL, JHZ, SJS and JMMH performed analyses and/or provided statistical guidance. IB, SB, MB, HB, EB, IBB, LAC, KLM, PBM, SJS, MW, LTA, JD, DFE, ML, CL, MIM, JSP, PV, SOR, PD, JD, MOG, SK, JBM, MGE, NJW, DMW supervised analyses. RAS, DFF, LL, MGE, NJW, DMW wrote the manuscript, with input from all authors.

Competing interests: J.L. A, M.G. E, L. L, and D.M. W are GSK stockholders. All named authors are solely responsible for the content of the manuscript. The current manuscript was a collaborative effort between academic and GSK scientists and analyses focused on a subset of genes included in the original sequencing paper (8), which focused on target genes of interest to GlaxoSmithKline. Since October 2015, D.F. has been a full time employee of Bayer AG, Germany.

Data and materials availability: Data on glycemic traits were contributed by MAGIC investigators and were downloaded from www.magicinvestigators.org. Associations with T2D in a GWAS of Europeans were obtained from The DIAGRAM (DIABetes Genetics Replication And Meta-analysis) investigators (<http://diagram-consortium.org/downloads.html>).

that these agents may be associated with benefit, a question currently being addressed in randomised controlled trials. Genetic variants associated with metabolic traits and multiple disease outcomes can be used to validate therapeutic targets at an early stage in the drug development process.

Introduction

In 2008, the US Food and Drug Administration issued guidance for industry on new therapies to treat type 2 diabetes (T2D), recommending that sponsors should demonstrate that these treatments are “not associated with an unacceptable increase in cardiovascular risk” (1). This mandate challenges drug developers to prove safety during clinical trials, which is an expensive and late-phase strategy for the identification of such concerns. Instead, genetic approaches may aid in the identification of possible drug side-effects much earlier in the drug development process. Genetic variants can inform the treatment and prevention of human disease (2, 3), either reducing the prioritisation of potential targets (4, 5) or implicating new targets (6, 7). Functional exonic variants can be useful surrogates for drug effects, when, for example, a loss-of-function (LoF) variant may be a useful tool to understand the consequences of pharmacological inhibition of a particular target protein (7). Recent sequencing efforts have identified a large number of potentially functional low-frequency and rare exonic variants in human populations, even among genes under purifying selection (8–12). Although such variants may influence susceptibility to disease, the high cost of these sequencing approaches has previously meant that they have not been performed in the sample sizes required to allow routine investigation of their association with complex disease and related traits.

A recent targeted exome sequencing study of 202 genes encoding potential drug targets identified an abundance of potentially functional exonic variants (8). Among these 202 genes, six genes encoding drug targets licensed or in development by GlaxoSmithKline (GSK) for treatment of obesity and/or T2D were included. Recognizing that these data could be used to test for genetic variants mimicking pharmacological manipulation of the encoded protein (drug target), we investigated six genes encoding targets of relevance to obesity and T2D. These variants could then serve as tools to aid the broader evaluation of drug-related risk for adverse events mediated via on-target effects.

As a proof of concept for use of genetic variants to evaluate the cardiovascular safety of anti-diabetic agents, we evaluated the widely used glucose-lowering glucagon-like peptide-1 receptor (GLP1R) agonists (13). These agents are long-acting mimetics of the incretin hormone GLP1, which increases insulin secretion after oral consumption of glucose but not after glucose administered intravenously. There are uncertainties over the role of these agents in the aetiology of rare, adverse pancreatic events that have been reported following their usage (14). These therapies have been associated with weight loss (15) and reduced cardiovascular risk factors, and while a recent trial reported non-inferiority of GLP1R-agonists in cardiovascular safety (16), multiple trials evaluating cardiovascular safety have not yet been completed (17). We used a genetic variant in *GLP1R* that is associated with variation in fasting glucose levels and with T2D risk (18) to evaluate the cardiovascular

safety of GLP1R agonists. The low-frequency variant protective for T2D was also protective for coronary heart disease (CHD). These findings support the notion that GLP1R agonists will not confer an increased cardiovascular risk in people. This study also demonstrates how genetic target validation approaches can be employed early in the drug development process to evaluate efficacy and safety.

Results

Association of genetic variants in genes encoding T2D and obesity drug targets

The study design consisted of initial discovery of variants with suggestive associations, to targeted genotyping and *in silico* follow-up analyses (Fig. 1). We investigated the association of 121 variants in six genes encoding therapeutic targets in use or in development for T2D or obesity (*CNR2*, *DPP4*, *GLP1R*, *SLC5A1*, *HTR2C*, *MCHR1*)—drawn from a recent targeted exome sequencing study of 202 genes encoding drug targets (8)—with variation in the following traits: T2D, obesity, body-mass index (BMI), waist circumference, fasting glucose, fasting insulin, and 2-h glucose (Fig. 1). In the “Discovery Analysis”, we identified seven variants potentially associated with T2D- or obesity-related traits (where $p < 0.001$, or which were in a target of interest to GSK and $p < 0.05$) (Table 1). For these seven variants, “Follow-Up Analysis” was performed by targeted genotyping in up to 39,979 additional individuals of European ancestry. Where possible, *in silico* follow-up analysis was performed for traits and variants available in large-scale genetic consortia data.

Initial discovery analyses included 1331 tests of association, with the threshold specified to reach significance in combined analyses being $p < 3.8 \times 10^{-5}$. In a combined analysis of results from the different phases, we identified a low-frequency (~1% minor allele frequency (MAF)) missense variant Ala316Thr; rs10305492 in the *GLP1R* gene to be associated with fasting glucose (Fig. 2A). The variant was in Hardy-Weinberg equilibrium in all genotyped samples ($p > 0.2$). The effect size (i.e. the difference per allele) of 0.09 mM was larger than most common variants previously reported for fasting glucose (Fig. 2B), and was recently found to be associated with fasting glucose in non-overlapping samples from large-scale analyses of coding variant associations with glycaemic traits (18). The combined analysis of the six other variants in Table 1 did not show evidence of association ($p > 3.8 \times 10^{-5}$, by linear or logistic regression) with the suggestively associated trait in the discovery analysis (“Follow-up” p -values > 0.05 ; “Combined” p -values = 0.005; Table 1).

The *GLP1R* gene encodes the GLP1 receptor, the target for GLP-1, a hormone that mediates the augmented response to insulin secretion following oral glucose administration. This receptor is the target for the GLP1R-agonist class of T2D therapeutics and the association of this variant with fasting glucose mimicked a major effect of this class of agents. To further corroborate the utility of this variant as a surrogate indicator of pharmacological modulation of the receptor, we investigated its association with T2D and found that the minor allele was associated with lower risk of T2D [odds ratio (OR) = 0.83 [0.76, 0.91]; $P = 9.4 \times 10^{-5}$; in a fixed effect meta-analysis of log-odds ratios from studies and consortia listed in table S1 and in Supplementary Materials “Studies contributing to follow-up analyses of type-2 diabetes and obesity related traits”; $n_{\text{cases}} = 25,868$, $n_{\text{controls}} = 122,393$]. However, we saw no

association of this *GLP1R* variant (Ala316Thr; rs10305492) with fasting insulin, nor with 2-h glucose (Fig. 2A).

Although there were no individuals carrying putative LoF variants in *GLP1R* in the targeted sequencing study, a single individual in the cohort-arm of the UK10K study had a LoF allele (W297*) but did not have an extreme glycaemic phenotype. This individual's fasting glucose and insulin concentrations were within the range of 95% of the values for this population. Nine high-confidence LoF variants in *GLP1R* were observed in the ExAC database (19). Eight were singletons and the most common had a frequency of less than 1/10,000, highlighting the difficulty in restricting analyses to individual LoF variants.

Association of *GLP1R* variant with quantitative traits and comparison with effects observed in clinical trials of GLP1R agonists

To further characterise the extent to which the *GLP1R* variant associations mirrored the effects of GLP1R-agonist therapy, we compared genetic associations to the metabolic effects observed in previously reported clinical trials (Fig. 3, table S2). GLP1R agonist therapy can result in lower fasting and post-challenge glucose, weight loss, a reduction in systolic blood pressure, reduced total- and LDL-cholesterol and an increase in resting heart rate. The effects of GLP1R-agonists on glycaemic measures (fasting glucose and 2-h glucose) were stronger than those on non-glycaemic factors (Fig. 3), which have been detectable only in some meta-analyses of clinical trials (20–23).

Using fasting glucose as the benchmark, the per-allele association of the genetic variant with glucose (-0.15 SDs [$-0.20, -0.11$], from Fig. 2) was 3.3-fold weaker than the effect observed for GLP1R-agonist treatment (-0.49 [$-0.60, -0.37$], from Fig. 3). We therefore rescaled the genetic associations to account for this difference, by multiplying the magnitude of all observed genetic associations by 3.3 (Fig. 3), and demonstrated that there was little difference between the magnitude of association of the *GLP1R* variant and effects observed in clinical trials beyond that expected by chance ($\alpha=0.0025$). An exception to this observation was the impact of GLP1R agonist therapy on weight in non-diabetic individuals when compared to the observed association between the variant and BMI ($p=2.6\times 10^{-4}$, Cochrane's Q test) (table S2). The genetic variant was not associated with BMI (Fig. 3), whereas the agonist therapy caused a reduction in body mass in non-diabetic individuals but not in individuals with T2D (fig. S1, table S2). However, five of the six trials in non-diabetic individuals were performed in obese participants (table S3), whose higher starting weight may have enabled a greater weight loss.

GLP1R agonists appeared to have a greater effect on 2-h glucose than the magnitude of association observed for the variant ($p=2.1\times 10^{-12}$, Cochrane's Q test) (Fig. 3; fig. S2; table S2). The difference was most pronounced in comparison to trials in individuals with T2D, among whom we observed heterogeneity in the effect of GLP1R agonists on 2-h glucose, even within drug class ($I^2=97\%$) (fig. S2B). There was no significant difference between the magnitude of genetic association and the impact of GLP1R agonist therapy on 2-h glucose in non-diabetic individuals (Fig. 3; table S2), although the number of people included in such trials was much smaller than in trials including individuals with T2D (table S3).

Association of GLP1R variant with disease outcomes

Our final aim was to describe the association of the *GLP1R* variant with CHD and other outcomes. In a large-scale international collaboration, we studied 61,846 individuals with CHD and 163,728 controls, and found that the fasting glucose-lowering allele of *GLP1R* was associated with protection against CHD (Fig. 4). The association with CHD is greater than the 1% reduction in risk that would be predicted based on the association of this variant with fasting glucose alone (24) (see Supplementary Methods on “Calculating the reduction in coronary heart disease risk attributable to lower fasting glucose levels”), suggesting that lowering of fasting glucose alone is unlikely to explain the observed association between the *GLP1R* variant and lower risk of CHD. Although not significant, carriage of the minor allele was associated with lower LDL cholesterol, triglycerides, systolic blood pressure, and higher HDL cholesterol.

Using data from international consortia, we found no evidence for association of the *GLP1R* variant with pancreatic cancer, although the confidence intervals were wide owing to the comparatively small sample size (4987 cases and 8627 controls) and low frequency of the allele (Fig. 4). There was no evidence of association with breast, ovarian, or prostate cancer risk. Given the interest in GLP1R agonist therapy for neurological disease, including Parkinson's (25) and Alzheimer's (26), we also investigated the association of the *GLP1R* variant with those diseases, but found no evidence of association (Fig. 4).

Discussion

Anticipating the side effects of drugs prior to phase III clinical trials could support drug discovery and development, reducing attrition rates and saving considerable time and money. The promise of human genetics in this endeavour (2, 3, 7, 27) depends on the availability of genetic variants that mimic pharmaceutical interventions. We undertook a systematic study to identify such genetic variants in the context of diabetes and obesity, and identified an association between fasting glucose and T2D with a missense variant in *GLP1R*, the gene encoding the GLP-1 receptor—the target of the GLP1R agonist class of T2D therapies. Regulatory authorities require evidence that therapies for T2D are not associated with unacceptable increases in cardiovascular risk. The reduced risk associated with the glucose-lowering genetic variant in *GLP1R* provides evidence that not only will GLP1R agonists meet this regulatory hurdle, but they may also reduce CHD events. Ongoing trials of GLP1R agonists are designed to resolve this uncertainty and will also augment the evidence on the broader validity of genetic approaches in drug-target validation.

A key consideration in assessing whether genetic variants can be used to understand therapeutic effects is how well the genetic variant mirrors the effects of pharmacological intervention at the same target. Genetic association data, here and reported previously (18), suggest that lifelong carriage of the minor *GLP1R* allele (at rs10305492) is associated with lower fasting glucose and lower risk of T2D, although not with 2-h glucose. Clinical trial data from individuals with T2D, who may have a diminished incretin effect, show that GLP1R agonists lower 2-h glucose considerably (28), whereas the effect on 2-h glucose is smaller in individuals without T2D (29), presumably because non-diabetic individuals are less likely to have an impaired incretin effect requiring therapeutic correction. Similarly,

GLP1R agonists were associated with greater weight loss in obese individuals than in non-obese. Such a phenomenon has previously been suggested for the effects of GLP1R-agonism on blood pressure, where GLP1R-agonist therapy appears to lower blood pressure in individuals with high blood pressure but not in non-hypertensive individuals (30, 31). This highlights a limitation in the use of genetic variants in target validation: that the association of genetic variants is often tested in individuals of “normal” physiology, whereas clinical trials are generally performed in individuals with prevalent disease.

An important step in evaluating the utility of genomics in target validation is to understand the functional consequences of variants. For potential novel targets, whether the variant confers gain or loss of function informs the development of either an agonist or antagonist therapy. For example, LoF variants have been used to understand the consequences of antagonism of a novel drug target (7, 32). However, researchers have gained insights using variants validated as instruments when their phenotypic associations mirrored pharmacological action, even in the absence of strong functional insights into the mechanism of those variants (33). GLP1R-agonist therapy reduces fasting glucose in humans, as does administration of GLP1, regardless of the duration or severity of T2D (34). In mice, the loss of GLP1R leads to fasting hyperglycaemia (35, 36). Together, these findings in humans and in mice suggest that the glucose-lowering minor allele at rs10305492 confers gain of function. However, differences in basal activity of the human and murine GLP1R (37) limit our ability to extrapolate findings from *GLP1R* knockout mice to humans (15, 32). Previous attempts to characterise the effect of this variant in cellular models have been inconclusive (38, 39). The rarity of putative LoF alleles in the *GLP1R* impaired our ability to restrict analyses to such variants. Although the absence of definitive functional characterisation is a limitation of this study, our observation that the minor allele is strongly associated with lower fasting glucose levels and is protective against T2D supports the validity of the variant as a genetic instrument for GLP1R-agonist therapy. Future integration of large-scale human genetic data with functional characterisation in appropriate cell models will allow broader application of variants, other than those characterised as LoF, in target validation.

Although the *GLP1R* variant was not associated with any of the other non-glycaemic or quantitative cardiovascular parameters, there was insufficient evidence to suggest the genetic associations and pharmacological effects were different. Power calculations indicated that, to detect the expected association with systolic blood pressure or resting heart rate, a sample size of more than 250,000 individuals would be required. This is considerably larger than most current genetic consortia, although this limitation could soon be overcome as larger studies become available (40), further strengthening the promise of genomics in target validation. Although we did not observe overall evidence for association of variants other than the *GLP1R* variant, the discovery phase, from which we selected variants for follow-up, was relatively small in comparison to the overall sample and there remains a possibility of type II error in the discovery phase. As larger resources of genetic data become available, these potential concerns will also be reduced.

The detection of rare adverse effects of a drug remains a challenge. Pharmacological approaches using routine database analysis may identify rare adverse

outcomes associated with treatment, but the approach is rarely conclusive because of confounding, particularly by indication. Our demonstration that the *GLP1R* variant is not associated with pancreatic, breast, prostate, or ovarian cancer, or with Parkinson's or Alzheimer's disease is limited by the upper bounds of the confidence intervals, which are too high to allow strong inference about the likely long-term safety of GLP1R agonists with regard to these outcomes. Although these data represent the largest resources available globally, the accumulation of studies with greater numbers of individuals with genetic data and robust disease outcome classification will considerably enhance the potential of this type of investigation. The comparisons of other traits and disease outcomes, beyond the primary indications, makes the assumption that pharmacological effects are mediated via “on-target” effects and not “off-target” effects (i.e. those mediated by effects of the agent on other non-specific targets). Although our results offer insight into the effects of GLP1R agonists, they do not necessarily apply to other agents targeting the incretin pathway through different mechanisms, such as by DPP-4 inhibition (41).

In conclusion, through a targeted exome sequencing approach, we identified that a low-frequency missense variant in *GLP1R* was associated with lower fasting glucose and risk of T2D, similar to the effects of GLP1R agonist therapy. This variant was also associated with lower risk of CHD, thus providing supportive evidence that these agents are not likely to be associated with an unacceptable increase in cardiovascular risk and may indeed be associated with benefit, a question currently being addressed in randomised controlled trials. We propose that future drug development and investment decisions could be informed by genomic data much earlier in the development process, providing insight into both efficacy and side-effects.

Methods

Study design

We studied six genes encoding therapeutic targets licensed or in development for obesity or T2D (*CNR2*, *DPP4*, *GLP1R*, *SLC5A1*, *HTR2C*, *MCHR1*), drawn from a recent targeted exome sequencing study of 202 genes encoding drug targets (8), which represented approximately 1% of the coding genome and 7% of all genes considered current or potential drug targets (8). In the “Discovery Analysis”, we investigated the association of common and rare variants in these six genes with seven T2D and obesity-related traits (Fig. 1). We analysed all variants which had i) MAF \geq 0.5% or well imputed ($R^2 > 0.5$) in CoLaus; ii) MAF \geq 0.5% in GEMS; or iii) MAF \geq 0.1% in BMI (given the larger sample size) in the CoLaus study (42), the GEMS study (43), or all individuals with BMI measurements. We examined 121 variants for association with six traits in the CoLaus study ($6 \times 121 = 726$ tests); 4 traits in GEMS ($4 \times 121 = 484$ tests); and 1 trait in the BMI study, comprising a total of 1331 tests of association. First, we analysed a subset of the population-based CoLaus study ($n=2086$) for T2D, obesity, waist circumference, fasting glucose, fasting insulin, and 2-h glucose traits. Second, in the GEMS dyslipidaemic case and normolipidaemic control study ($n_{\text{cases}}=787$, $n_{\text{controls}}=792$), we analysed obesity, waist circumference, fasting glucose, and fasting insulin traits. We performed discovery analyses in the CoLaus and GEMS studies separately due to the different study designs and traits analysed in attempt to

maximise sensitivity to detect associations that might be masked by context-dependent associations. Third, BMI measures were available in a larger sample size from 11 studies (Fig. 1), and were analysed together. We provide the sample sizes for the discovery analyses in Figure 1 and trait-specific sample sizes in Table 1 ($n = 505 - 11,806$). We augmented the sequence data for the CoLaus study with imputed data in the remainder of the study ($n=3539$) where variants were imputable ($R^2>0.5$) using a custom imputation process on individuals genotyped on the Affymetrix 500K chip but not included in the targeted sequencing experiment (Supplementary Materials).

Using results from the discovery analyses, we identified variants that were associated with T2D or obesity-related traits at the $p<0.001$ level or were located in genes encoding targets of strategic interest to GSK, including *GLP1R*, *DPP4*, *CNR2*, and *HTR2C* with a p value threshold of <0.05 . To maximise sensitivity to detect associations in these genes of highest interest, we took forward to follow up those variants reaching $p<0.05$ in the discovery analyses. However, this did not affect the threshold for statistical significance or overall alpha value (3.8×10^{-5}), for which we accounted for all association tests performed in the discovery analyses ($N=1331$). The principal reason for prioritising specific genes was to ensure a balance between sensitivity for targets of high priority to GSK and to maintain specificity: given that initial replication was performed by de novo large-scale targeted genotyping, we were practically unable to follow up vast numbers of variants. This does not bias the variants selected for follow-up, nor raise the risk of type I error. Indeed, the only variant we determined to be mimicking pharmacological manipulation was well beyond “genome-wide significance” even if all possible low-frequency and common variants in the genome had been tested.

We then genotyped seven variants in six genes in up to 39,979 follow-up participants of European ancestry drawn from multiple studies (Fig. 1): CoLaus (when GEMS was the discovery sample), GEMS (when CoLaus was the discovery set), Ely (44) ($n=1722$), EPIC-Norfolk (45) ($n=25313$), Fenland (46) ($n=6379$), and LOLIPOP (47) ($n=6565$) studies. The follow-up analysis of T2D included participants from the Norfolk Diabetes Study ($N_{\text{cases}}=5587$ and $N_{\text{controls}}=19012$), GenOA study ($N_{\text{cases}}=129$ and $N_{\text{controls}}=1501$), and individuals with T2D from the ADDITION study (48) ($N_{\text{cases}}=816$) who were combined with additional cases from the Ely study ($N_{\text{cases}}=116$) and compared to non-diabetic controls from the Ely study ($N_{\text{controls}}=1487$).

We also sought further *in silico* follow-up Analysis to further evaluate associations in collaborative studies utilizing results from the MAGIC and CHARGE consortia. Five of the seven variants were available for *in silico* analysis (table 1). Further details on each of the studies and consortia are provided in the Supplementary Materials and table S1 and S4.

Statistical analyses

We carried out genetic association analyses on variants identified via targeted sequencing using an additive genetic model by linear or logistic regression, adjusting for age and sex and other study-specific covariates. We combined study-specific estimates using fixed effect meta-analysis. We performed analyses on standardised variables (mean=0 and SD=1) and, as such, expressed effect sizes as standard deviations (SDs) for quantitative traits. In total,

we analysed 121 single nucleotide variants (SNVs). Overall, we performed 1,331 tests of association in the discovery analyses and, as such, associations that were $\alpha < 3.8 \times 10^{-5}$ in the combined analysis were deemed to be statistically significant.

We performed targeted genotyping of selected variants from discovery analyses using Sequenom for the Ely, EPIC-Norfolk, Fenland, and ADDITION studies and KASPar for the LOLIPOP study. Imputed data were also available in the GenOA study using reference haplotypes from participants in the previous sequencing study (8). We carried out genetic association analyses in each study under an additive genetic model using linear or logistic regression, again adjusting for age, sex and study-specific covariates. We sought further *in silico* follow-up from summary association results from MAGIC and CHARGE consortia (table 1). We converted summary association result effect sizes to SDs using the SD of fasting glucose from the population-based Fenland study ($SD = 0.65$ mM) (46). We meta-analyzed results from the discovery analysis, follow-up analysis and *in silico* follow-up analysis using a fixed effect, inverse-variance weighted approach. The discovery analysis of the CoLaus study included association results from the sequence variants and imputed variants (table 1). In the entire CoLaus study, we later directly genotyped (KASPar technology) variants which had been imputed in the unsequenced CoLaus participants study as part of the original follow-up analysis. The combined analysis results in table 1 therefore represent those from the directly genotyped data.

For variants that showed statistically significant associations in the combined analysis ($p < 3.8 \times 10^{-5}$), we investigated their association with a range of anthropometric, metabolic, and cardiovascular risk factors and disease outcomes in the studies described previously, as well as in additional studies described in table S1 and S4 and in Supplementary Materials. We also investigated the association of variants reaching statistical significance after follow up ($\alpha < 3.8 \times 10^{-5}$) with coronary heart disease (CHD) through targeted genotyping and collaboration with large-scale Exome chip consortia (table S1). For these variants, we also investigated association with a range of other disease outcomes (table S1), with a particular focus on diseases previously suggested as potential opportunities for repositioning (i.e. where existing drugs might be used for alternative indications). However, as the variant reaching statistical significance was not well covered on existing GWAS arrays or in HapMap, we were limited to those disease outcomes for which we could obtain association data. For genes that contained variants with $p < 3.8 \times 10^{-5}$ in the combined analysis, we investigated the presence of putative LoF alleles in individuals in whom we had performed targeted sequencing (8) and in individuals with whole-genome sequencing from the UK10K study (www.uk10k.org).

Comparison of clinical trial effects and genetic associations

Randomized clinical trials of GLP1R-agonists were identified through previous systematic reviews and by performing a supplementary literature search, as detailed in the Supplementary Materials. Only trials with placebo or no-drug comparison groups (i.e. no trials with active comparison groups), with 4 weeks drug treatment (i.e. no single dose studies) and 10 participants per trial arm were included. Treatment effects were expressed in SDs before pooling across trials using random effects meta-analysis (see table S3 for

details of clinical trials included). P-values derived from Cochrane's Q test were used as a guide to assess whether there were pairwise differences between the rescaled genetic and trial estimates.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Authors

Robert A. Scott^{1,‡}, Daniel F. Freitag^{2,3,‡}, Li Li^{4,‡,§}, Audrey Y. Chu⁵, Praveen Surendran², Robin Young², Niels Grarup⁶, Alena Stancáková⁷, Yuning Chen⁸, Tibor V.Varga⁹, Hanieh Yaghootkar¹⁰, Jian'an Luan¹, Jing Hua Zhao¹, Sara M. Willems^{1,11}, Jennifer Wessel^{12,13}, Shuai Wang⁸, Nisa Maruthur^{14,15,16}, Kyriaki Michailidou¹⁷, Ailith Pirie¹⁷, Sven J. van der Lee¹⁸, Christopher Gillson¹, Ali Amin Al Olama¹⁷, Philippe Amouyel¹⁹, Larraitz Arriola^{20,21,22}, Dominique Arveiler²³, Iciar Aviles-Olmos²⁴, Beverley Balkau^{25,26}, Aurelio Barricarte^{27,22}, Inês Barroso^{3,28}, Sara Benlloch Garcia¹⁷, Joshua C. Bis²⁹, Stefan Blankenberg³⁰, Michael Boehnke³¹, Heiner Boeing³², Eric Boerwinkle^{33,34}, Ingrid B. Borecki³⁵, Jette Bork-Jensen⁶, Sarah Bowden³⁶, Carlos Caldas³⁷, Muriel Caslake³⁸, The CVD50 consortium, L. Adrienne Cupples^{8,39}, Carlos Cruchaga⁴⁰, Jacek Czajkowski⁴¹, Marcel den Hoed⁴², Janet A. Dunn⁴³, Helena M. Earl⁴⁴, Georg B. Ehret⁴⁵, Ele Ferrannini⁴⁶, Jean Ferrieres⁴⁷, Thomas Foltynie²⁴, Ian Ford³⁸, Nita G. Forouhi¹, Francesco Gianfagna^{48,49}, Carlos Gonzalez⁵⁰, Sara Grioni⁵¹, Louise Hiller⁴³, Jan-Håkan Jansson^{52,53}, Marit E. Jørgensen^{54,55}, J. Wouter Jukema⁵⁶, Rudolf Kaaks⁵⁷, Frank Kee⁵⁸, Nicola D. Kerrison¹, Timothy J. Key⁵⁹, Jukka Kontto⁶⁰, Zsafia Kote-Jarai⁶¹, Aldi T. Kraja⁴¹, Kari Kuulasmaa⁶⁰, Johanna Kuusisto^{62,63}, Allan Linneberg^{64,65,66}, Chunyu Liu⁶⁷, Gaëlle Marenne³, Karen L. Mohlke⁶⁸, Andrew P. Morris^{69,70}, Kenneth Muir^{71,72}, Martina Müller-Nurasyid^{73,74,75}, Patricia B. Munroe⁷⁶, Carmen Navarro^{77,22}, Sune F. Nielsen⁷⁸, Peter M. Nilsson⁷⁹, Børge G. Nordestgaard⁷⁸, Chris J. Packard³⁸, Domenico Palli⁸⁰, Salvatore Panico⁸¹, Gina M. Peloso^{82,83,84}, Markus Perola^{85,60}, Annette Peters^{86,75}, Christopher J. Poole^{87,72}, J. Ramón Quirós⁸⁸, Olov Rolandsson⁸⁹, Carlotta Sacerdote^{90,91,92}, Veikko Salomaa⁶⁰, María-José Sánchez^{93,22}, Naveed Sattar³⁸, Stephen J. Sharp¹, Rebecca Sims⁹⁴, Nadia Slimani⁹⁵, Jennifer A. Smith⁹⁶, Deborah J. Thompson¹⁷, Stella Trompet⁵⁶, Rosario Tumino⁹⁷, Daphne L. van der A⁹⁸, Yvonne T. van der Schouw⁹⁹, Jarmo Virtamo⁶⁰, Mark Walker¹⁰⁰, Klaudia Walter³, GERAD_EC Consortium[†], Neurology working group Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE), Alzheimer's Disease Genetics Consortium[†], Pancreatic Cancer Cohort Consortium, EPIC-CVD, EPIC-InterAct, Jean E. Abraham¹⁰¹, Laufey T. Amundadottir¹⁰², Jennifer L. Aponte^{103,§}, Adam S. Butterworth², Josée Dupuis⁸, Douglas F. Easton^{17,101}, Rosalind A. Eeles^{61,104}, Jeanette Erdmann¹⁰⁵, Paul W. Franks^{9,53,106}, Timothy M. Frayling¹⁰, Torben Hansen⁶, Joanna M. M. Howson², Torben Jørgensen^{107,108,109}, Jaspal Kooner^{110,111,112}, Markku Laakso¹¹³, Claudia Langenberg¹, Mark I. McCarthy^{114,70}, James S. Pankow¹¹⁵, Oluf Pedersen⁶, Elio Riboli¹¹⁶, Jerome I.

Rotter¹¹⁷, Danish Saleheen¹¹⁸, Nilesh J. Samani^{119,120}, Heribert Schunkert^{75,121}, Peter Vollenweider¹²², Stephen O'Rahilly^{28,123,124}, CHARGE consortium, The CHD Exome+ consortium, CARDIOGRAM Exome consortium, Panos Deloukas¹²⁵, John Danesh^{2,3}, Mark O. Goodarzi¹²⁶, Sekar Kathiresan^{127,128,83}, James B. Meigs^{129,130}, Margaret G. Ehm¹⁰³, Nicholas J. Wareham¹, and Dawn M. Waterworth¹³¹

Affiliations

¹Medical Research Council Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge Biomedical Campus, Cambridge, UK ²Department of Public Health and Primary Care, Strangeways Research Laboratory, University of Cambridge, Cambridge, UK ³The Wellcome Trust Sanger Institute, Cambridge, UK ⁴Statistical Genetics, Projects, Clinical Platforms & Sciences, GlaxoSmithKline, Research Triangle Park, NC, USA ⁵Division of Preventive Medicine, Brigham and Women's Hospital, Boston MA, USA ⁶The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark ⁷Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland, Kuopio, Finland ⁸Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA ⁹Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, Lund University, Malmö, Sweden ¹⁰Genetics of Complex Traits, University of Exeter Medical School, University of Exeter, Exeter, UK ¹¹Genetic Epidemiology Unit, Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands ¹²Fairbanks School of Public Health, Department of Epidemiology, Indianapolis, IN, US ¹³Indiana University School of Medicine, Department of Medicine, Indianapolis, IN, USA ¹⁴Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA ¹⁵Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, Maryland ¹⁶Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland ¹⁷Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Laboratory, Worts Causeway, Cambridge, UK ¹⁸Department of Epidemiology, Erasmus University Medical Center, Rotterdam, Netherlands ¹⁹University of Lille, Institut national de la santé et de la recherche médicale (Inserm), Centre Hospitalier Régional Universitaire de Lille, Institut Pasteur de Lille, UMR1167 - RID-AGE, F-59000 Lille, France ²⁰Public Health Division of Gipuzkoa, San Sebastian, Spain ²¹Instituto BIO-Donostia, Basque Government, San Sebastian, Spain ²²CIBER Epidemiología y Salud Pública (CIBERESP), Spain ²³Department of Epidemiology and Public Health (EA3430), University of Strasbourg, Strasbourg, France ²⁴Sobell Department of Motor Neuroscience, UCL Institute of Neurology, London, UK ²⁵Inserm, Centre de recherche en épidémiologie et santé des populations (CESP), Villejuif, France ²⁶Univ Paris-Sud, Villejuif, France ²⁷Navarre Public Health Institute (ISPN), Pamplona, Spain ²⁸University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Cambridge, UK

²⁹Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, USA ³⁰Department of General and Interventional Cardiology, University Heart Center Hamburg, Germany ³¹Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, MI, USA ³²German Institute of Human Nutrition, Potsdam-Rehbruecke, Germany ³³Human Genetics Center, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX, USA ³⁴Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA ³⁵Department of Genetics, Division of Statistical Genomics, Washington University School of Medicine, St. Louis, MO, USA ³⁶Cancer Research UK Clinical Trials Unit, Institute for Cancer Studies, The University of Birmingham, Edgbaston, Birmingham, UK ³⁷Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK ³⁸University of Glasgow, Glasgow, UK ³⁹National Heart, Lung, and Blood Institute (NHLBI) Framingham Heart Study, Framingham, MA, USA ⁴⁰Dep. of Psychiatry, Washington University, School of Medicine, St. Louis, MO, US ⁴¹Division of Statistical Genomics, Department of Genetics and Center for Genome Sciences and Systems Biology, Washington University School of Medicine, St. Louis, MO, USA ⁴²Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden ⁴³Warwick Clinical Trials Unit, University of Warwick, Gibbet Hill Road, Coventry, UK ⁴⁴University of Cambridge and National Institute of Health Research Cambridge Biomedical Research Centre at Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, UK ⁴⁵McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, MD, USA ⁴⁶Consiglio Nazionale delle Ricerche (CNR) Institute of Clinical Physiology, Pisa, Italy ⁴⁷Department of Epidemiology, UMR 1027- INSERM, Centre Hospitalier Universitaire (CHU) de Toulouse, Toulouse, France ⁴⁸Department of Clinical and Experimental Medicine, Research Centre in Epidemiology and Preventive Medicine, University of Insubria, Varese, Italy ⁴⁹Department of Epidemiology and Prevention, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Neurologico Mediterraneo Neuromed, Pozzilli, Italy ⁵⁰Catalan Institute of Oncology (ICO), Barcelona, Spain ⁵¹Epidemiology and Prevention Unit, Milan, Italy ⁵²Research Unit, Skellefteå, Sweden ⁵³Department of Public Health & Clinical Medicine, Umeå University, Umeå, Sweden ⁵⁴Steno Diabetes Center, Gentofte, Denmark ⁵⁵National Institute of Public Health, Southern Denmark University, Denmark ⁵⁶Leiden University Medical Center, Leiden, Netherlands ⁵⁷German Cancer Research Centre (DKFZ), Heidelberg, Germany ⁵⁸UK Clinical Research Collaboration (UKCRC) Centre of Excellence for Public Health, Queens University Belfast, Northern Ireland, UK ⁵⁹University of Oxford, UK ⁶⁰National Institute for Health and Welfare, Helsinki, Finland ⁶¹The Institute of Cancer Research, London, UK ⁶²Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland, Kuopio, Finland ⁶³Kuopio University Hospital, Kuopio, Finland ⁶⁴Research Centre for Prevention and Health, Capital region, Copenhagen, Denmark ⁶⁵Department of Clinical Experimental Research, Rigshospitalet, Glostrup, Denmark ⁶⁶Department of Clinical Medicine,

Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark ⁶⁷Framingham Heart Study, Population Sciences Branch, NHLBI/NIH, Bethesda, MD, USA ⁶⁸Department of Genetics, University of North Carolina, Chapel Hill, NC, USA ⁶⁹Department of Biostatistics, University of Liverpool, Liverpool, UK ⁷⁰Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK ⁷¹The University of Manchester, Centre for Epidemiology, Institute of Population Health, Oxford Road, Manchester, UK ⁷²University of Warwick, Coventry, UK ⁷³Institute of Genetic Epidemiology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany ⁷⁴Department of Medicine I, Ludwig-Maximilians-University Munich, Munich, Germany ⁷⁵DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany ⁷⁶Clinical Pharmacology, William Harvey Research Institute, Barts and The London, Queen Mary University of London, London, UK ⁷⁷Department of Epidemiology, Murcia Regional Health Council-IMIB Arrixaca, Murcia, Spain ⁷⁸Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen, Denmark ⁷⁹Lund University, Malmö, Sweden ⁸⁰Cancer Research and Prevention Institute (ISPO), Florence, Italy ⁸¹Dipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy ⁸²Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA, USA ⁸³Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA ⁸⁴Program in Medical and Population Genetics, Broad Institute, Cambridge, MA, USA ⁸⁵Institute of Molecular Medicine Finland (FIMM), University of Helsinki ⁸⁶Institute of Epidemiology II, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany ⁸⁷Department of Medical Oncology, Arden Cancer Centre, University Hospital Coventry and Warwickshire ⁸⁸Public Health Directorate, Asturias, Spain ⁸⁹Umeå University, Umeå, Sweden ⁹⁰Unit of Cancer Epidemiology, Citta' della Salute e della Scienza Hospital-University of Turin ⁹¹Center for Cancer Prevention (CPO), Torino, Italy ⁹²Human Genetics Foundation (HuGeF), Torino, Italy ⁹³Escuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria ibs.GRANADA. Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain ⁹⁴Institute of Psychological Medicine and Clinical Neuroscience, MRC Centre, Cardiff University, UK ⁹⁵International Agency for Research on Cancer, Lyon, France ⁹⁶Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, USA ⁹⁷Cancer Registry and Histopathology Unit, "Civic M.P.Arezzo" Hospital, ASP Ragusa (Italy) ⁹⁸National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands ⁹⁹University Medical Center Utrecht, Utrecht, The Netherlands ¹⁰⁰Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK ¹⁰¹Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Strangeways Laboratory, Worts Causeway, Cambridge, UK ¹⁰²Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA ¹⁰³Genetics, PCPS, GlaxoSmithKline, RTP, NC, USA ¹⁰⁴Royal Marsden NHS Foundation Trust, Fulham and Sutton, London and Surrey,

UK ¹⁰⁵Institut für Integrative und Experimentelle Genomik, Universität zu Lübeck, Lübeck, Germany ¹⁰⁶Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, MA, USA ¹⁰⁷Research Centre for Prevention and Health, Capital region, Denmark ¹⁰⁸Department of Public Health, Institute of Health Science, University of Copenhagen, Denmark ¹⁰⁹Faculty of Medicine, Aalborg University, Denmark ¹¹⁰National Heart and Lung Institute, Imperial College London, London, UK ¹¹¹Imperial College Healthcare NHS Trust, London, UK ¹¹²Ealing Hospital NHS Trust, Middlesex, UK ¹¹³Department of Medicine, University of Kuopio, Kuopio, Finland ¹¹⁴Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM), University of Oxford, UK ¹¹⁵Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, USA ¹¹⁶School of Public Health, Imperial College London, UK ¹¹⁷Institute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research Institute at Harbor-University of California, Los Angeles (UCLA) Medical Center, Torrance, CA, USA ¹¹⁸Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, USA ¹¹⁹Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester, UK ¹²⁰National Institute for Health Research (NIHR) Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, UK ¹²¹Deutsches Herzzentrum München, Technische Universität München, Munich, Germany ¹²²Department of Internal Medicine, BH10-462, Internal Medicine, Lausanne University Hospital (CHUV), Lausanne, Switzerland ¹²³MRC Metabolic Diseases Unit, Cambridge, UK ¹²⁴National Institute of Health Research Cambridge Biomedical Research Centre, Cambridge, UK ¹²⁵William Harvey Research Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, UK ¹²⁶Division of Endocrinology, Diabetes and Metabolism, Cedars-Sinai Medical Center, Los Angeles, CA, USA ¹²⁷Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA ¹²⁸Cardiology Division, Center for Human Genetic Research, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA ¹²⁹Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA ¹³⁰Department of Medicine, Harvard Medical School, Boston, MA, USA ¹³¹Genetics, Projects, Clinical Platforms & Sciences, GlaxoSmithKline, Philadelphia, PA, USA

Acknowledgments

We are grateful for the contributions of the studies and consortia which provided summary results. For a complete list of Acknowledgements, see Supplementary Materials.

Funding: The work described in this manuscript was funded, in part, by GSK, and, in part, by the Medical Research Council (MC_UU_12015/1). CHARGE AD analyses were funded by R01 AG033193 (PI Seshadri). ADGC AD analyses were funded by U01AG032984 (PI Schellenberg). Additional funding sources are outlined in the Supplementary Materials.

The authors would like to thank the Exome Aggregation Consortium and the groups that provided exome variant data for comparison. A full list of contributing groups can be found at <http://exac.broadinstitute.org/about>. Additional materials can be obtained by request to the corresponding authors and may be subject to MTA requirements.

References and notes

1. US FDA. Guidance for Industry Diabetes Mellitus — Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. 2008. <http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf>
2. Plenge RM, Scolnick EM, Altshuler D. Validating therapeutic targets through human genetics. *Nat Rev Drug Discov*. 2013; 12:581–594. [PubMed: 23868113]
3. Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, Floratos A, Sham PC, Li MJ, Wang J, Cardon LR, Whittaker JC, Sanseau P. The support of human genetic evidence for approved drug indications. *Nat Genet*. 2015; 47:856–860. [PubMed: 26121088]
4. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, Hindy G, Hólm H, Ding EL, Johnson T, Schunkert H, Samani NJ, Clarke R, Hopewell JC, Thompson JF, Li M, Thorleifsson G, Newton-Cheh C, Musunuru K, Pirruccello JP, Saleheen D, Chen L, Stewart AFR, Schillert A, Thorsteinsdottir U, Thorgeirsson G, Anand S, Engert JC, Morgan T, Spertus J, Stoll M, Berger K, Martinelli N, Girelli D, McKeown PP, Patterson CC, Epstein SE, Devaney J, Burnett MS, Mooser V, Ripatti S, Surakka I, Nieminen MS, Sinisalo J, Lokki ML, Perola M, Havulinna A, de Faire U, Gigante B, Ingelsson E, Zeller T, Wild P, de Bakker PIW, Klungel OH, Maitland-van der Zee AH, Peters BJM, de Boer A, Grobbee DE, Kamphuisen PW, Deneer VHM, Elbers CC, Onland-Moret NC, Hofker MH, Wijmenga C, Verschuren WMM, a Boer JM, van der Schouw YT, Rasheed A, Frossard P, Demissie S, Willer C, Do R, Ordovas JM, Abecasis GR, Boehnke M, Mohlke KL, Daly MJ, Guiducci C, Burt NP, Surti A, Gonzalez E, Purcell S, Gabriel S, Marrugat J, Peden J, Erdmann J, Diemert P, Willenborg C, König IR, Fischer M, Hengstenberg C, Ziegler A, Buyschaert I, Lambrechts D, Van de Werf F, Fox KA, El Mokhtari NE, Rubin D, Schrezenmeir J, Schreiber S, Schäfer A, Danesh J, Blankenberg S, Roberts R, McPherson R, Watkins H, Hall AS, Overvad K, Rimm E, Boerwinkle E, Tybjaerg-Hansen A, Cupples LA, Reilly MP, Melander O, Mannucci PM, Ardisino D, Siscovick D, Elosua R, Stefansson K, O'Donnell CJ, Salomaa V, Rader DJ, Peltonen L, Schwartz SM, Altshuler D, Kathiresan S. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. *Lancet*. 2012; 380:572–80. [PubMed: 22607825]
5. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. *N Engl J Med*. 2008; 359:1897–1908. [PubMed: 18971492]
6. Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. *N Engl J Med*. 2006; 354:1264–72. [PubMed: 16554528]
7. Myocardial Infarction Genetics Consortium Investigators. Inactivating Mutations in NPC1L1 and Protection from Coronary Heart Disease. *N Engl J Med*. 2014 141112140016008.
8. Nelson MR, Wegmann D, Ehm MG, Kessner D, St Jean P, Verzilli C, Shen J, Tang Z, Bacanu SA, Fraser D, Warren L, Aponte J, Zawistowski M, Liu X, Zhang H, Zhang Y, Li J, Li Y, Li L, Woollard P, Topp S, Hall MD, Nangle K, Wang J, Abecasis G, Cardon LR, Zöllner S, Whittaker JC, Chisoe SL, Novembre J, Mooser V. An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. *Science*. 2012; 337:100–4. [PubMed: 22604722]
9. Keinan A, Clark AG. Recent explosive human population growth has resulted in an excess of rare genetic variants. *Science*. 2012; 336:740–3. [PubMed: 22582263]
10. Tennessen JA, Bigham AW, O'Connor TD, Fu W, Kenny EE, Gravel S, Mc Gee S, Do R, Liu X, Jun G, Kang HM, Jordan D, Leal SM, Gabriel S, Rieder MJ, Abecasis G, Altshuler D, Nickerson Da, Boerwinkle E, Sunyaev S, Bustamante CD, Bamshad MJ, Akey JM. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. *Science*. 2012; 337:64–9. [PubMed: 22604720]
11. Coventry A, Bull-Otterson LM, Liu X, Clark AG, Maxwell TJ, Crosby J, Hixson JE, Rea TJ, Muzny DM, Lewis LR, Wheeler Da, Sabo A, Lusk C, Weiss KG, Akbar H, Cree A, Hawes AC, Newsham I, Varghese RT, Villasana D, Gross S, Joshi V, Santibanez J, Morgan M, Chang K, Iv WH, Templeton AR, Boerwinkle E, Gibbs R, Sing CF. Deep resequencing reveals excess rare recent variants consistent with explosive population growth. *Nat Commun*. 2010; 1:131. [PubMed: 21119644]

12. Fu W, O'Connor TD, Jun G, Kang HM, Abecasis G, Leal SM, Gabriel S, Rieder MJ, Altshuler D, Shendure J, Nickerson Da, Bamshad MJ, Akey JM. Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants. *Nature*. 2013; 493:216–20. [PubMed: 23201682]
13. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. *Nat Rev Endocrinol*. 2009; 5:262–9. [PubMed: 19444259]
14. Cure P, Pileggi A, Alejandro R. Exenatide and rare adverse events. *N Engl J Med*. 2008; 358:1969–70. discussion 1971–2. [PubMed: 18450614]
15. Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF, Lean MEJ. NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. *Lancet (London, England)*. 2009; 374:1606–16.
16. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJV, Probstfield JL, Riddle MC, Solomon SD, Tardif JC. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. *N Engl J Med*. 2015; 373:2247–2257. [PubMed: 26630143]
17. Sivertsen J, Rosenmeier J, Holst JJ, Vilsbøll T. The effect of glucagon-like peptide 1 on cardiovascular risk. *Nat Rev Cardiol*. 2012; 9:209–22. [PubMed: 22290234]
18. Wessel J, Chu AY, Willems SM, Wang S, Yaghootkar H, Brody JA, Dauriz M, Hivert MF, Raghavan S, Lipovich L, Hidalgo B, Fox K, Huffman JE, An P, Lu Y, Rasmussen-Torvik LJ, Grarup N, Ehm MG, Li L, Baldridge AS, Stan áková A, Abrol R, Besse C, Boland A, Bork-Jensen J, Fornage M, Freitag DF, Garcia ME, Guo X, Hara K, Isaacs A, Jakobsdottir J, Lange LA, Layton JC, Li M, Hua Zhao J, Meidtner K, Morrison AC, Nalls MA, Peters MJ, Sabater-Lleal M, Schurmann C, Silveira A, Smith AV, Southam L, Stoiber MH, Strawbridge RJ, Taylor KD, Varga TV, Allin KH, Amin N, Aponte JL, Aung T, Barbieri C, Bihlmeyer NA, Boehnke M, Bombieri C, Bowden DW, Burns SM, Chen Y, Chen YD, Cheng CY, Correa A, Czajkowski J, Dehghan A, Ehret GB, Eiriksdottir G, Escher SA, Farmaki AE, Fränberg M, Gambaro G, Giulianini F, Goddard WA, Goel A, Gottesman O, Grove ML, Gustafsson S, Hai Y, Hallmans G, Heo J, Hoffmann P, Ikram MK, Jensen RA, Jørgensen ME, Jørgensen T, Karaleftheri M, Khor CC, Kirkpatrick A, Kraja AT, Kuusisto J, Lange EM, Lee IT, Lee WJ, Leong A, Liao J, Liu C, Liu Y, Lindgren CM, Linneberg A, Malerba G, Mamakou V, Marouli E, Maruthur NM, Matchan A, Mc Kean-Cowdin R, Mc Leod O, Metcalf GA, Mohlke KL, Muzny DM, Ntalla I, Palmer ND, Pasko D, Peter A, Rayner NW, Renström F, Rice K, Sala CF, Sennblad B, Serafetinidis I, Smith JA, Soranzo N, Speliotes EK, Stahl EA, Stirrups K, Tentolouris N, Thanopoulou A, Torres M, Traglia M, Tsafantakis E, Javad S, Yanek LR, Zengini E, Becker DM, Bis JC, Brown JB, Adrienne Cupples L, Hansen T, Ingelsson E, Karter AJ, Lorenzo C, Mathias RA, Norris JM, Peloso GM, Sheu WHH, Toniolo D, Vaidya D, Varma R, Wagenknecht LE, Boeing H, Bottinger EP, Dedoussis G, Deloukas P, Ferrannini E, Franco OH, Franks PW, Gibbs RA, Gudnason V, Hamsten A, Harris TB, Hattersley AT, Hayward C, Hofman A, Jansson JH, Langenberg C, Launer LJ, Levy D, Oostra BA, O'Donnell CJ, O'Rahilly S, Padmanabhan S, Pankow JS, Polasek O, Province MA, Rich SS, Ridker PM, Rudan I, Schulze MB, Smith BH, Uitterlinden AG, Walker M, Watkins H, Wong TY, Zeggini E, Laakso M, Borecki IB, Chasman DI, Pedersen O, Psaty BM, Shyong Tai E, van Duijn CM, Wareham NJ, Waterworth DM, Boerwinkle E, Linda Kao WH, Florez JC, Loos RJF, Wilson JG, Frayling TM, Siscovick DS, Dupuis J, Rotter JJ, Meigs JB, Scott RA, Goodarzi MO. Low-frequency and rare exome chip variants associate with fasting glucose and type 2 diabetes susceptibility. *Nat Commun*. 2015; 6:5897. [PubMed: 25631608]
19. Lek M, Karczewski K, Minikel E, Samocha K, Banks E, Fennell T, O'Donnell-Luria A, Ware J, Hill A, Cummings B, Tukiainen T, Birnbaum D, Kosmicki J, Duncan L, Estrada K, Zhao F, Zou J, Pierce-Hoffman E, Cooper D, DePristo M, Do R, Flannick J, Fromer M, Gauthier L, Goldstein J, Gupta N, Howrigan D, Kiezun A, Kurki M, Moonshine AL, Natarajan P, Orozco L, Peloso G, Poplin R, Rivas M, Ruano-Rubio V, Ruderfer D, Shakir K, Stenson P, Stevens C, Thomas B, Tiao G, Tusie-Luna M, Weisburd B, Won HH, Yu D, Altshuler D, Ardissino D, Boehnke M, Danesh J, Roberto E, Florez J, Gabriel S, Getz G, Hultman C, Kathiresan S, Laakso M, McCarroll S, McCarthy M, McGovern D, McPherson R, Neale B, Palotie A, Purcell S, Saleheen D, Scharf J, Sklar P, Patrick S, Tuomilehto J, Watkins H, Wilson J, Daly M, MacArthur D. Exome Aggregation Consortium. Analysis of protein-coding genetic variation in 60,706 humans. 2015; doi: 10.1101/030338

20. Moreno JL, Willett KC, Desilets AR. Exenatide as a novel weight loss modality in patients without diabetes. *Ann Pharmacother.* 2012; 46:1700–6. [PubMed: 23191935]
21. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. *BMJ.* 2012; 344:d7771. [PubMed: 22236411]
22. Robinson LE, Holt TA, Rees K, Randeve HS, O'Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. *BMJ Open.* 2013; 3doi: 10.1136/bmjopen-2012-001986
23. Schmidt LJ, Habacher W, Augustin T, Krahulec E, Semlitsch T. A systematic review and meta-analysis of the efficacy of lixisenatide in the treatment of patients with type 2 diabetes. *Diabetes Obes Metab.* 2014; doi: 10.1111/dom.12269
24. The Emerging Risk Factors Collaboration, Diabetes mellitus, fasting glucose, and risk of cause-specific death. *N Engl J Med.* 2011; 364:829–41. [PubMed: 21366474]
25. Harkavyi A, Abuirmeileh A, Lever R, Kingsbury AE, Biggs CS, Whitton PS. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. *J Neuroinflammation.* 2008; 5:19. [PubMed: 18492290]
26. Li Y, Duffy KB, Ottinger MA, Ray B, Bailey Ja, Holloway HW, Tweedie D, Perry T, Mattson MP, Kapogiannis D, Sambamurti K, Lahiri DK, Greig NH. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. *J Alzheimers Dis.* 2010; 19:1205–19. [PubMed: 20308787]
27. Gregory AP, Dendrou Ca, Attfield KE, Haghikia A, Xifara DK, Butter F, Poschmann G, Kaur G, Lambert L, Leach Oa, Prömel S, Punwani D, Felce JH, Davis SJ, Gold R, Nielsen FC, Siegel RM, Mann M, Bell JI, Mc Vean G, Fugger L. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. *Nature.* 2012; 488:508–11. [PubMed: 22801493]
28. Kjems LL, Holst JJ, Vølund A, Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. *Diabetes.* 2003; 52:380–386. [PubMed: 12540611]
29. Dushay J, Gao C, Gopalakrishnan GS, Crawley M, Mitten EK, Wilker E, Mullington J, Maratos-Flier E. Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes. *Diabetes Care.* 2012; 35:4–11. [PubMed: 22040840]
30. Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. *Circ Res.* 2014; 114:1788–803. [PubMed: 24855202]
31. Grimm M, Han J, Weaver C, Griffin P, Schulteis CT, Dong H, Malloy J. Efficacy, safety and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials. *Postgrad Med.* 2013; 125:47–57.
32. Flannick J, Thorleifsson G, Beer NL, Jacobs SBR, Grarup N, Burt NP, Mahajan A, Fuchsberger C, Atzmon G, Benediktsson R, Blangero J, Bowden DW, Brandslund I, Brosnan J, Burslem F, Chambers J, Cho YS, Christensen C, Douglas DA, Duggirala R, Dymek Z, Farjoun Y, Fennell T, Fontanillas P, Forsén T, Gabriel S, Glaser B, Gudbjartsson DF, Hanis C, Hansen T, Hreidarsson AB, Hveem K, Ingelsson E, Isomaa B, Johansson S, Jørgensen T, Jørgensen ME, Kathiresan S, Kong A, Kooner J, Kravic J, Laakso M, Lee JY, Lind L, Lindgren CM, Linneberg A, Masson G, Meitinger T, Mohlke KL, Molven A, Morris AP, Potluri S, Rauramaa R, Ribel-Madsen R, Richard A, Rolph T, Salomaa V, Segrè AV, Skärstrand H, Steinhorsdottir V, Stringham HM, Sulem P, Tai ES, Teo YY, Teslovich T, Thorsteinsdottir U, Trimmer JK, Tuomi T, Tuomilehto J, Vaziri-Sani F, Voight BF, Wilson JG, Boehnke M, McCarthy MI, Njølstad PR, Pedersen O, Groop L, Cox DR, Stefansson K, Altshuler D. Loss-of-function mutations in SLC30A8 protect against type 2 diabetes. *Nat Genet.* 2014; 46:357–63. [PubMed: 24584071]
33. Swardlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JEL, Shah T, Sofat R, Stender S, Johnson PCD, Scott Ra, Leusink M, Verweij N, Sharp SJ, Guo Y, Giambartolomei C, Chung C, Peasey A, Amuzu A, Li K, Palmen J, Howard P, Cooper Ja, Drenos F, Li YR, Lowe G, Gallacher J, Stewart MCW, Tzoulaki I, Buxbaum SG, van der DL, Forouhi ANG, Onland-Moret NC, van der Schouw YT, Schnabel RB, Hubacek Ja, Kubinova R, Baceviciene M, Tamosiunas A, Pajak A, Topor-Madry R, Stepaniak U, Malyutina S, Baldassarre D, Sennblad B, Tremoli E, de Faire U, Veglia F, Ford I, Jukema JW, Westendorp RGJ, de Borst GJ, de Jong Pa, Algra A, Spiering W, der Zee AHM, Klungel OH, de Boer A, Doevendans Pa, Eaton CB, Robinson JG, Duggan D,

Kjekshus J, Downs JR, Gotto AM, Keech AC, Marchioli R, Tognoni G, Sever PS, Poulter NR, Waters DD, Pedersen TR, Amarenco P, Nakamura H, McMurray JJV, Lewsey JD, Chasman DI, Ridker PM, Maggioni AP, Tavazzi L, Ray KK, Seshasai SRK, Manson JE, Price JF, Whincup PH, Morris RW, Lawlor Da, Smith GD, Ben-Shlomo Y, Schreiner PJ, Fornage M, Siscovick DS, Cushman M, Kumari M, Wareham NJ, Verschuren WMM, Redline S, Patel SR, Whittaker JC, Hamsten A, Delaney Ja, Dale C, Gaunt TR, Wong A, Kuh D, Hardy R, Kathiresan S, Castillo Ba, van der Harst P, Brunner EJ, Tybjaerg-Hansen A, Marmot MG, Krauss RM, Tsai M, Coresh J, Hoogeveen RC, Psaty BM, Lange La, Hakonarson H, Dudbridge F, Humphries SE, Talmud PJ, Kivimäki M, Timpson NJ, Langenberg C, Asselbergs FW, Voevoda M, Bobak M, Pikhart H, Wilson JG, Reiner AP, Keating BJ, Hingorani AD, Sattar N. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. *Lancet*. 2014;1–11.

34. Toft-Nielsen MB, Madsbad S, Holst JJ. Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes. *J Clin Endocrinol Metab*. 2001; 86:3853–3860. [PubMed: 11502823]
35. Scrocchi LA, Brown TJ, Ma Clusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJ. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. *Nat Med*. 1996; 2:1254–8. [PubMed: 8898756]
36. Ayala JE, Bracy DP, James FD, Burmeister Ma, Wasserman DH, Drucker DJ. Glucagon-like peptide-1 receptor knockout mice are protected from high-fat diet-induced insulin resistance. *Endocrinology*. 2010; 151:4678–87. [PubMed: 20685876]
37. Seifert R, Wenzel-Seifert K. Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. *Naunyn Schmiedebergs Arch Pharmacol*. 2002; 366:381–416. [PubMed: 12382069]
38. Fortin J, Schroeder JC, Zhu Y, Beinborn M, Kopin AS. Pharmacological characterization of human incretin receptor missense variants. *J Pharmacol Exp Ther*. 2010; 332:274–80. [PubMed: 19841474]
39. Koole C, Wootten D, Simms J, Valant C, Miller LJ, Christopoulos A, Sexton PM. Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function: allosteric rescue of loss of function mutation. *Mol Pharmacol*. 2011; 80:486–97. [PubMed: 21616920]
40. Collins R. What makes UK Biobank special? *Lancet*. 2012; 379:1173–4. [PubMed: 22463865]
41. Drucker DJ, Nauck Ma. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. *Lancet*. 2006; 368:1696–705. [PubMed: 17098089]
42. Firmann M, Mayor V, Vidal PM, Bochud M, Pécoud A, Hayoz D, Paccaud F, Preisig M, Song KS, Yuan X, Danoff TM, Stirnadel Ha, Waterworth D, Mooser V, Waeber G, Vollenweider P. The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome. *BMC Cardiovasc Disord*. 2008; 8:6. [PubMed: 18366642]
43. Wyszynski DF, Waterworth DM, Barter PJ, Cohen J, Kesäniemi YA, Mahley RW, Mc Pherson R, Waeber G, Bersot TP, Sharma SS, Nolan V, Middleton LT, Sundseth SS, Farrer La, Mooser V, Grundy SM. Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project). *Am J Cardiol*. 2005; 95:194–8. [PubMed: 15642551]
44. Forouhi NG, Luan J, Hennings S, Wareham NJ. Incidence of Type 2 diabetes in England and its association with baseline impaired fasting glucose: the Ely study 1990–2000. *Diabet Med*. 2007; 24:200–7. [PubMed: 17257284]
45. Day N, Oakes S, Luben R, Khaw KT, Bingham S, Welch A, Wareham N. EPIC-Norfolk: study design and characteristics of the cohort. *European Prospective Investigation of Cancer. Br J Cancer*. 1999; 80(1):95–103. [PubMed: 10466767]
46. Rolfe EDL, Loos RJF, Druet C, Stolk RP, Ekelund U, Griffin SJ, Forouhi NG, Wareham NJ, Ong KK. Association between birth weight and visceral fat in adults. *Am J Clin Nutr*. 2010; 92:347–52. [PubMed: 20519560]
47. Kooner JS, Chambers JC, Aguilar-Salinas Ca, Hinds DA, Hyde CL, Warnes GR, Gómez Pérez FJ, Frazer Ka, Elliott P, Scott J, Milos PM, Cox DR, Thompson JF. Genome-wide scan identifies

variation in MLXIPL associated with plasma triglycerides. *Nat Genet.* 2008; 40:149–51. [PubMed: 18193046]

48. Echouffo-Tcheugui JB, Simmons RK, Williams KM, Barling RS, Prevost aT, Kinmonth AL, Wareham NJ, Griffin SJ. The ADDITION-Cambridge trial protocol: a cluster -- randomised controlled trial of screening for type 2 diabetes and intensive treatment for screen-detected patients. *BMC Public Health.* 2009; 9:136. [PubMed: 19435491]
49. Saxena R, Hivert MF, Langenberg C, Tanaka T, Pankow JS, Vollenweider P, Lyssenko V, Bouatia-Naji N, Dupuis J, Jackson AU, Kao WHL, Li M, Glazer NL, Manning AK, Luan J, Stringham HM, Prokopenko I, Johnson T, Grarup N, Boesgaard TW, Lecoeur C, Shrader P, O'Connell J, Ingelsson E, Couper DJ, Rice K, Song K, Andreasen CH, Dina C, Köttgen A, Le Bacquer O, Pattou F, Taneera J, Steinthorsdottir V, Rybin D, Ardlie K, Sampson M, Qi L, van Hoek M, Weedon MN, Aulchenko YS, Voight BF, Grallert H, Balkau B, Bergman RN, Bielinski SJ, Bonnycastle LL, Borch-Johnsen K, Böttcher Y, Brunner E, Buchanan Ta, Bumpstead SJ, Cavalcanti-Proença C, Charpentier G, Chen YDI, Chines PS, Collins FS, Cornelis M, Crawford GJ, Delplanque J, Doney A, Egan JM, Erdos MR, Firmann M, Forouhi NG, Fox CS, Goodarzi MO, Graessler J, Hingorani A, Isomaa B, Jørgensen T, Kivimaki M, Kovacs P, Krohn K, Kumari M, Lauritzen T, Lévy-Marchal C, Mayor V, Mc Ateer JB, Meyre D, Mitchell BD, Mohlke KL, Morken Ma, Narisu N, Palmer CNa, Pakyz R, Pascoe L, Payne F, Pearson D, Rathmann W, Sandbaek A, Sayer AA, Scott LJ, Sharp SJ, Sijbrands E, Singleton A, Siscovick DS, Smith NL, Sparsø T, Swift AJ, Syddall H, Thorleifsson G, Tönjes A, Tuomi T, Tuomilehto J, Valle TT, Waeber G, Walley A, Waterworth DM, Zeggini E, Zhao JH, Illig T, Wichmann HE, Wilson JF, van Duijn C, Hu FB, Morris AD, Frayling TM, Hattersley AT, Thorsteinsdottir U, Stefansson K, Nilsson P, Syvänen AC, Shuldiner AR, Walker M, Bornstein SR, Schwarz P, Williams GH, Nathan DM, Kuusisto J, Laakso M, Cooper C, Marmot M, Ferrucci L, Mooser V, Stumvoll M, Loos RJJ, Altshuler D, Psaty BM, Rotter JI, Boerwinkle E, Hansen T, Pedersen O, Florez JC, Mc Carthy MI, Boehnke M, Barroso I, Sladek R, Froguel P, Meigs JB, Groop L, Wareham NJ, Watanabe RM. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. *Nat Genet.* 2010; 42:142–8. [PubMed: 20081857]
50. Scott RA, Lagou V, Welch RP, Wheeler E, Montasser ME, Luan J, Mägi R, Strawbridge RJ, Rehnberg E, Gustafsson S, Kanoni S, Rasmussen-Torvik LJ, Yengo L, Lecoeur C, Shungin D, Sanna S, Sidore C, Johnson PCD, Jukema JW, Johnson T, Mahajan A, Verweij N, Thorleifsson G, Hottenga JJ, Shah S, Smith AV, Sennblad B, Gieger C, Salo P, Perola M, Timpson NJ, Evans DM, Pourcain BS, Wu Y, Andrews JS, Hui J, Bielak LF, Zhao W, Horikoshi M, Navarro P, Isaacs A, O'Connell JR, Stirrups K, Vitart V, Hayward C, Esko T, Mihailov E, Fraser RM, Fall T, Voight BF, Raychaudhuri S, Chen H, Lindgren CM, Morris AP, Rayner NW, Robertson N, Rybin D, Liu CT, Beckmann JS, Willems SM, Chines PS, Jackson AU, Kang HM, Stringham HM, Song K, Tanaka T, Peden JF, Goel A, Hicks Aa, An P, Müller-Nurasyid M, Franco-Cereceda A, Folkersen L, Marullo L, Jansen H, Oldehinkel AJ, Bruinenberg M, Pankow JS, North KE, Forouhi NG, Loos RJJ, Edkins S, Varga TV, Hallmans G, Oksa H, Antonella M, Nagaraja R, Trompet S, Ford I, Bakker SJL, Kong A, Kumari M, Gigante B, Herder C, Munroe PB, Caulfield M, Antti J, Mangino M, Small K, Miljkovic I, Liu Y, Atalay M, Kiess W, James AL, Rivadeneira F, Uitterlinden AG, Palmer CNa, Doney ASF, Willemsen G, Smit JH, Campbell S, Polasek O, Bonnycastle LL, Herberg S, Dimitriou M, Bolton JL, Fowkes GR, Kovacs P, Lindström J, Zemunik T, Bandinelli S, Wild SH, Basart HV, Rathmann W, Grallert H, Maerz W, Kleber ME, Boehm BO, Peters A, Pramstaller PP, Province Ma, Borecki IB, Hastie ND, Rudan I, Campbell H, Watkins H, Farrall M, Stumvoll M, Ferrucci L, Waterworth DM, Bergman RN, Collins FS, Tuomilehto J, Watanabe RM, de Geus EJC, Penninx BW, Hofman A, Oostra Ba, Psaty BM, Vollenweider P, Wilson JF, Wright AF, Hovingh GK, Metspalu A, Uusitupa M, Magnusson PKE, Kyvik KO, Kaprio J, Price JF, Dedoussis GV, Deloukas P, Meneton P, Lind L, Boehnke M, Shuldiner AR, van Duijn CM, Morris AD, Toenjes A, Peyser Pa, Beilby JP, Körner A, Kuusisto J, Laakso M, Bornstein SR, Schwarz PEH, Lakka Ta, Rauramaa R, Adair LS, Smith GD, Spector TD, Illig T, de Faire U, Hamsten A, Gudnason V, Kivimaki M, Hingorani A, Keinanen-Kiukkaanniemi SM, Saaristo TE, Boomsma DI, Stefansson K, van der Harst P, Dupuis J, Pedersen NL, Sattar N, Harris TB, Cucca F, Ripatti S, Salomaa V, Mohlke KL, Balkau B, Froguel P, Pouta A, Jarvelin MR, Wareham NJ, Bouatia-Naji N, McCarthy MI, Franks PW, Meigs JB, Teslovich TM, Florez JC, Langenberg C, Ingelsson E, Prokopenko I, Barroso I. Large-scale association analyses identify new loci influencing glycemic

traits and provide insight into the underlying biological pathways. *Nat Genet.* 2012; 44:991–1005. [PubMed: 22885924]

51. Manning AK, Hivert MF, Scott RA, Grimsby JL, Bouatia-Naji N, Chen H, Rybin D, Liu CT, Bielak LF, Prokopenko I, Amin N, Barnes D, Cadby G, Hottenga JJ, Ingelsson E, Jackson AU, Johnson T, Kanoni S, Ladenvall C, Lagou V, Lahti J, Lecoeur C, Liu Y, Martinez-Larrad MT, Montasser ME, Navarro P, Perry JRB, Rasmussen-Torvik LJ, Salo P, Sattar N, Shungin D, Strawbridge RJ, Tanaka T, van Duijn CM, An P, de Andrade M, Andrews JS, Aspelund T, Atalay M, Aulchenko Y, Balkau B, Bandinelli S, Beckmann JS, Beilby JP, Bellis C, Bergman RN, Blangero J, Boban M, Boehnke M, Boerwinkle E, Bonnycastle LL, Boomsma DI, Borecki IB, Böttcher Y, Bouchard C, Brunner E, Budimir D, Campbell H, Carlson O, Chines PS, Clarke R, Collins FS, Corbatón-Anchuelo A, Couper D, de Faire U, Dedoussis GV, Deloukas P, Dimitriou M, Egan JM, Eiriksdottir G, Erdos MR, Eriksson JG, Eury E, Ferrucci L, Ford I, Forouhi NG, Fox CS, Franzosi MG, Franks PW, Frayling TM, Froguel P, Galan P, de Geus E, Gigante B, Glazer NL, Goel A, Groop L, Gudnason V, Hallmans G, Hamsten A, Hansson O, Harris TB, Hayward C, Heath S, Hercberg S, Hicks AA, Hingorani A, Hofman A, Hui J, Hung J, Jarvelin MR, Jhun Ma, Johnson PCD, Jukema JW, Julia A, Kao WH, Kaprio J, Kardia SLR, Keinanen-Kiukkaanniemi S, Kivimäki M, Kolcic I, Kovacs P, Kumari M, Kuusisto J, Kyvik KO, Laakso M, Lakka T, Lannfelt L, Lathrop GM, Launer LJ, Leander K, Li G, Lind L, Lindstrom J, Lobbens S, Loos RJF, Luan J, Lyssenko V, Mägi R, Magnusson PKE, Marmot M, Meneton P, Mohlke KL, Mooser V, Morken Ma, Miljkovic I, Narisu N, O'Connell J, Ong KK, Oostra BA, Palmer LJ, Palotie A, Pankow JS, Peden JF, Pedersen NL, Pehlic M, Peltonen L, Penninx B, Pericic M, Perola M, Perusse L, Peyser PA, Polasek O, Pramstaller PP, Province MA, Rääkkönen K, Rauramaa R, Rehnberg E, Rice K, Rotter JJ, Rudan I, Ruokonen A, Saaristo T, Sabater-Lleal M, Salomaa V, Savage DB, Saxena R, Schwarz P, Seedorf U, Sennblad B, Serrano-Rios M, Shuldiner AR, Sijbrands EJG, Siscovick DS, Smit JH, Small KS, Smith NL, Smith AV, Stanáková A, Stirrups K, Stumvoll M, Sun YV, Swift AJ, Tönjes A, Tuomilehto J, Trompet S, Uitterlinden AG, Uusitupa M, Vikström M, Vitart V, Vohl MC, Voight BF, Vollenweider P, Waeber G, Waterworth DM, Watkins H, Wheeler E, Widen E, Wild SH, Willems SM, Willemsen G, Wilson JF, Witteman JCM, Wright AF, Yaghootkar H, Zelenika D, Zemanick T, Zgaga L, Wareham NJ, McCarthy MI, Barroso I, Watanabe RM, Florez JC, Dupuis J, Meigs JB, Langenberg C. A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycaemic traits and insulin resistance. *Nat Genet.* 2012; 44:659–69. [PubMed: 22581228]
52. Johnson T, Gaunt TR, Newhouse SJ, Padmanabhan S, Tomaszewski M, Kumari M, Morris RW, Tzoulaki I, O'Brien ET, Poulter NR, Sever P, Shields DC, Thom S, Wannamethee SG, Whincup PH, Brown MJ, Connell JM, Dobson RJ, Howard PJ, Mein CA, Onipinla A, Shaw-Hawkins S, Zhang Y, Davey Smith G, Day INM, Lawlor DA, Goodall AH, Fowkes FG, Abecasis GR, Elliott P, Gateva V, Braund PS, Burton PR, Nelson CP, Tobin MD, van der Harst P, Glorioso N, Neuvirth H, Salvi E, Staessen JA, Stucchi A, Devos N, Jeunemaitre X, Plouin PF, Tichet J, Juhanson P, Org E, Putku M, Söber S, Veldre G, Viigimaa M, Levinsson A, Rosengren A, Thelle DS, Hastie CE, Hedner T, Lee WK, Melander O, Wahlstrand B, Hardy R, Wong A, Cooper JA, Palmen J, Chen L, Stewart AFR, Wells GA, Westra HJ, Wolfs MGM, Clarke R, Franzosi MG, Goel A, Hamsten A, Lathrop M, Peden JF, Seedorf U, Watkins H, Ouwehand WH, Sambrook J, Stephens J, Casas JP, Drenos F, Holmes MV, Kivimäki M, Shah S, Shah T, Talmud PJ, Whittaker J, Wallace C, Delle C, Laan M, Kuh D, Humphries SE, Nyberg F, Cusi D, Roberts R, Newton-Cheh C, Franke L, Stanton AV, Dominiczak AF, Farrall M, Hingorani AD, Samani NJ, Caulfield MJ, Munroe PB. Blood pressure loci identified with a gene-centric array. *Am J Hum Genet.* 2011; 89:688–700. [PubMed: 22100073]
53. den Hoed M, Eijgelsheim M, Esko T, Brundel BJM, Peal DS, Evans DM, Nolte IM, Segrè AV, Holm H, Handsaker RE, Westra HJ, Johnson T, Isaacs A, Yang J, Lundby A, Zhao JH, Kim YJ, Go MJ, Almgren P, Bochud M, Boucher G, Cornelis MC, Gudbjartsson D, Hadley D, van der Harst P, Hayward C, den Heijer M, Igl W, Jackson AU, Kutalik Z, Luan J, Kemp JP, Kristiansson K, Ladenvall C, Lorentzon M, Montasser ME, Njajou OT, O'Reilly PF, Padmanabhan S, St Pourcain B, Rankinen T, Salo P, Tanaka T, Timpson NJ, Vitart V, Waite L, Wheeler W, Zhang W, Draisma HHM, Feitosa MF, Kerr KF, Lind PA, Mihailov E, Onland-Moret NC, Song C, Weedon MN, Xie W, Yengo L, Absher D, Albert CM, Alonso A, Arking DE, de Bakker PIW, Balkau B, Barlassina C, Benaglio P, Bis JC, Bouatia-Naji N, Brage S, Chanock SJ, Chines PS, Chung M, Darbar D, Dina C, Dörr M, Elliott P, Felix SB, Fischer K, Fuchsberger C, de Geus EJC, Goyette P,

Gudnason V, Harris TB, Hartikainen AL, Havulinna AS, Heckbert SR, Hicks AA, Hofman A, Holewijn S, Hoogstra-Berends F, Hottenga JJ, Jensen MK, Johansson A, Junttila J, Kääb S, Kanon B, Ketkar S, Khaw KT, Knowles JW, Kooner AS, Kors JA, Kumari M, Milani L, Laiho P, Lakatta EG, Langenberg C, Leusink M, Liu Y, Luben RN, Lunetta KL, Lynch SN, Markus MRP, Marques-Vidal P, Mateo Leach I, McArdle WL, McCarroll SA, Medland SE, Miller KA, Montgomery GW, Morrison AC, Müller-Nurasyid M, Navarro P, Nelis M, O'Connell JR, O'Donnell CJ, Ong KK, Newman AB, Peters A, Polasek O, Pouta A, Pramstaller PP, Psaty BM, Rao DC, Ring SM, Rossin EJ, Rudan D, Sanna S, Scott RA, Sehmi JS, Sharp S, Shin JT, Singleton AB, Smith AV, Soranzo N, Spector TD, Stewart C, Stringham HM, Tarasov KV, Uitterlinden AG, Vandenput L, Hwang SJ, Whitfield JB, Wijmenga C, Wild SH, Willemsen G, Wilson JF, Witteman JCM, Wong A, Wong Q, Jamshidi Y, Zitting P, Boer JMA, Boomsma DI, Borecki IB, van Duijn CM, Ekelund U, Forouhi NG, Froguel P, Hingorani A, Ingelsson E, Kivimäki M, Kronmal RA, Kuh D, Lind L, Martin NG, Oostra BA, Pedersen NL, Quertermous T, Rotter JJ, van der Schouw YT, Verschuren WMM, Walker M, Albanes D, Arner DO, Assimes TL, Bandinelli S, Boehnke M, de Boer RA, Bouchard C, Caulfield WLM, Chambers JC, Curhan G, Cusi D, Eriksson J, Ferrucci L, van Gilst WH, Glorioso N, de Graaf J, Groop L, Gyllenstein U, Hsueh WC, Hu FB, Huikuri HV, Hunter DJ, Iribarren C, Isomaa B, Jarvelin MR, Jula A, Kähönen M, Kiemeny LA, van der Klauw MM, Kooner JS, Kraft P, Iacoviello L, Lehtimäki T, Lokki MLL, Mitchell BD, Navis G, Nieminen MS, Ohlsson C, Poulter NR, Qi L, Raitakari OT, Rimm EB, Rioux JD, Rizzi F, Rudan I, Salomaa V, Sever PS, Shields DC, Shuldiner AR, Sinisalo J, Stanton AV, Stolk RP, Strachan DP, Tardif JC, Thorsteinsdóttir U, Tuomilehto J, van Veldhuisen DJ, Virtamo J, Viikari J, Vollenweider P, Waeber G, Widen E, Cho YS, Olsen JV, Visscher PM, Willer C, Franke L, Erdmann J, Thompson JR, Pfeuffer A, Sotoodehnia N, Newton-Cheh C, Ellinor PT, Stricker BHC, Metspalu A, Perola M, Beckmann JS, Smith GD, Stefansson K, Wareham NJ, Munroe PB, Sibon OCM, Milan DJ, Snieder H, Samani NJ, Loos RJF. Identification of heart rate-associated loci and their effects on cardiac conduction and rhythm disorders. *Nat Genet.* 2013; 45:621–31. [PubMed: 23583979]

54. Mailman MD, Feolo M, Jin Y, Kimura M, Tryka K, Bagoutdinov R, Hao L, Kiang A, Paschall J, Phan L, Popova N, Pretel S, Ziyabari L, Lee M, Shao Y, Wang ZY, Sirotkin K, Ward M, Kholodov M, Zbicz K, Beck J, Kimelman M, Shevelev S, Preuss D, Yaschenko E, Graeff A, Ostell J, Sherry ST. The NCBI dbGaP database of genotypes and phenotypes. *Nat Genet.* 2007; 39:1181–6. [PubMed: 17898773]
55. Wolpin BM, Rizzato C, Kraft P, Kooperberg C, Petersen GM, Wang Z, Arslan AA, Beane-Freeman L, Bracci PM, Buring J, Canzian F, Duell EJ, Gallinger S, Giles GG, Goodman GE, Goodman PJ, Jacobs EJ, Kamineni A, Klein AP, Kolonel LN, Kulke MH, Li D, Malats N, Olson SH, Risch HA, Sesso HD, Visvanathan K, White E, Zheng W, Abnet CC, Albanes D, Andreotti G, Austin MA, Barfield R, Basso D, Berndt SI, Boutron-Ruault MC, Brotzman M, Büchler MW, Bueno-de-Mesquita HB, Bugert P, Burdette L, Campa D, Caporaso NE, Capurso G, Chung C, Cotterchio M, Costello E, Elena J, Funel N, Gaziano JM, Giese NA, Giovannucci EL, Goggins M, Gorman MJ, Gross M, Haiman CA, Hassan M, Helzlsouer KJ, Henderson BE, Holly EA, Hu N, Hunter DJ, Innocenti F, Jenab M, Kaaks R, Key TJ, Khaw KT, Klein EA, Kogevinas M, Krogh V, Kupcinskis J, Kurtz RC, La Croix A, Landi MT, Landi S, Le Marchand L, Mambrini A, Mannisto S, Milne RL, Nakamura Y, Oberg AL, Owzar K, Patel AV, Peeters PHM, Peters U, Pezzilli R, Piepoli A, Porta M, Real FX, Riboli E, Rothman N, Scarpa A, Shu XO, Silverman DT, Soucek P, Sund M, Talar-Wojnarowska R, Taylor PR, Theodoropoulos GE, Thornquist M, Tjønneland A, Tobias GS, Trichopoulos D, Vodicka P, Wactawski-Wende J, Wentzensen N, Wu C, Yu H, Yu K, Zeleniuch-Jacquotte A, Hoover R, Hartge P, Fuchs C, Chanock SJ, Stolzenberg-Solomon RS, Amundadottir LT. Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. *Nat Genet.* 2014; 46:994–1000. [PubMed: 25086665]
56. Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, DeStefano AL, Kara E, Bras J, Sharma M, Schulte C, Keller MF, Arepalli S, Letson C, Edsall C, Stefansson H, Liu X, Pliner H, Lee JH, Cheng R, Ikram MA, Ioannidis JPA, Hadjigeorgiou GM, Bis JC, Martinez M, Perlmutter JS, Goate A, Marder K, Fiske B, Sutherland M, Xiromerisiou G, Myers RH, Clark LN, Stefansson K, Hardy JA, Heutink P, Chen H, Wood NW, Houlden H, Payami H, Brice A, Scott WK, Gasser T, Bertram L, Eriksson N, Foroud T, Singleton AB. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. *Nat Genet.* 2014; 056:1–7.
57. Zhang J, Kesteloot H. Anthropometric, lifestyle and metabolic determinants of resting heart rate. A population study. *Eur Heart J.* 1999; 20:103–10. [PubMed: 10099906]

58. Gauderman, J.; Ph, D.; Morrison, J. QUANTO 1.1: A computer program for power and sample size calculations for genetic-epidemiology studies; 2006. p. 35-50.<http://hydra.usc.edu/gxe>
59. Sarwar N, Gao P, Seshasai SRK, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor Da, Selvin E, Stampfer M, Stehouwer CDa, Lewington S, Pennells L, Thompson a, Sattar N, White IR, Ray KK, Danesh J. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. *Lancet*. 2010; 375:2215–22. [PubMed: 20609967]
60. Forouhi NG, Ye Z, Rickard AP, Khaw KT, Luben R, Langenberg C, Wareham NJ. Circulating 25-hydroxyvitamin D concentration and the risk of type 2 diabetes: results from the European Prospective Investigation into Cancer (EPIC)-Norfolk cohort and updated meta-analysis of prospective studies. *Diabetologia*. 2012; 55:2173–82. [PubMed: 22526608]
61. Swarbrick MM, Waldenmaier B, Pennacchio La, Lind DL, Cavazos MM, Geller F, Merriman R, Ustaszewska A, Malloy M, Scherag A, Hsueh WC, Rief W, Mauvais-Jarvis F, Pullinger CR, Kane JP, Dent R, Mc Pherson R, Kwok PY, Hinney A, Hebebrand J, Vaisse C. Lack of support for the association between GAD2 polymorphisms and severe human obesity. *PLoS Biol*. 2005; 3:e315. [PubMed: 16122350]
62. Langenberg C, Sharp S, Forouhi NG, Franks PW, Schulze MB, Kerrison N, Ekelund U, Barroso I, Panico S, Tormo MJ, Spranger J, Griffin S, van der Schouw YT, Amiano P, Ardanaz E, Arriola L, Balkau B, Barricarte a, Beulens JWJ, Boeing H, Bueno-de-Mesquita HB, Buijsse B, Chirlaque Lopez MD, Clavel-Chapelon F, Crowe FL, de Lauzon-Guillan B, Deloukas P, Dorronsoro M, Drogan D, Froguel P, Gonzalez C, Grioni S, Groop L, Groves C, Hainaut P, Halkjaer J, Hallmans G, Hansen T, Huerta Castaño JM, Kaaks R, Key TJ, Khaw KT, Koulman a, Mattiello a, Navarro C, Nilsson P, Norat T, Overvad K, Palla L, Palli D, Pedersen O, Peeters PH, Quirós JR, Ramachandran a, Rodriguez-Suarez L, Rolandsson O, Romaguera D, Romieu I, Sacerdote C, Sánchez MJ, Sandbaek a, Slimani N, Sluijs I, Spijkerman aMW, Teucher B, Tjønneland a, Tumino R, van der DL, Verschuren AWMM, Tuomilehto J, Feskens E, McCarthy M, Riboli E, Wareham NJ. Design and cohort description of the InterAct Project: an examination of the interaction of genetic and lifestyle factors on the incidence of type 2 diabetes in the EPIC Study. *Diabetologia*. 2011; 54:2272–82. [PubMed: 21717116]
63. Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, Charrondière UR, Hémon B, Casagrande C, Vignat J, Overvad K, Tjønneland a, Clavel-Chapelon F, Thiébaud a, Wahrendorf J, Boeing H, Trichopoulos D, Trichopoulou a, Vineis P, Palli D, Bueno-De-Mesquita HB, Peeters PHM, Lund E, Engeset D, González; Ca, Barricarte a, Berglund G, Hallmans G, Day NE, Key TJ, Kaaks R, Saracci R. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. *Public Health Nutr*. 2002; 5:1113–24. [PubMed: 12639222]
64. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. *JAMA*. 2007; 298:299–308. [PubMed: 17635890]
65. Danesh J, Saracci R, Berglund G, Feskens E, Overvad K, Panico S, Thompson S, Fournier A, Clavel-Chapelon F, Canonico M, Kaaks R, Linseisen J, Boeing H, Pischon T, Weikert C, Olsen A, Tjønneland A, Johnsen SP, Jensen MK, Quirós JR, Svatetz CAG, Pérez MJS, Larrañaga N, Sanchez CN, Iribas CM, Bingham S, Khaw KT, Wareham N, Key T, Roddam A, Trichopoulou A, Benetou V, Trichopoulos D, Masala G, Sieri S, Tumino R, Sacerdote C, Mattiello A, Verschuren WMM, Bueno-de-Mesquita HB, Grobbee DE, van der Schouw YT, Melander O, Hallmans G, Wennberg P, Lund E, Kumle M, Skeie G, Ferrari P, Slimani N, Norat T, Riboli E. EPIC-Heart: the cardiovascular component of a prospective study of nutritional, lifestyle and biological factors in 520,000 middle-aged participants from 10 European countries. *Eur J Epidemiol*. 2007; 22:129–41. [PubMed: 17295097]
66. Bingham S, Riboli E. Diet and cancer--the European Prospective Investigation into Cancer and Nutrition. *Nat Rev Cancer*. 2004; 4:206–15. [PubMed: 14993902]
67. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. *N Engl J Med*. 1995; 333:1301–7. [PubMed: 7566020]
68. Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry

- IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RGJ. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet*. 2002; 360:1623–30. [PubMed: 12457784]
69. Evans A, Salomaa V, Kulathinal S, Asplund K, Cambien F, Ferrario M, Perola M, Peltonen L, Shields D, Tunstall-Pedoe H, Kuulasmaa K. MORGAM (an international pooling of cardiovascular cohorts). *Int J Epidemiol*. 2005; 34:21–7. [PubMed: 15561751]
 70. Kulathinal S, Karvanen J, Saarela O, Kuulasmaa K. Case-cohort design in practice - experiences from the MORGAM Project. *Epidemiol Perspect Innov*. 2007; 4:15. [PubMed: 18053196]
 71. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. *Am J Epidemiol*. 1989; 129:687–702. [PubMed: 2646917]
 72. Assimes TL, Hólm H, Kathiresan S, Reilly MP, Thorleifsson G, Voight BF, Erdmann J, Willenborg C, Vaidya D, Xie C, Patterson CC, Morgan TM, Burnett MS, Li M, Hlatky MA, Knowles JW, Thompson JR, Absher D, Iribarren C, Go A, Fortmann SP, Sidney S, Risch N, Tang H, Myers RM, Berger K, Stoll M, Shah SH, Thorgeirsson G, Andersen K, Havulinna AS, Herrera JE, Faraday N, Kim Y, Kral BG, Mathias RA, Ruczinski I, Suktitipat B, Wilson AF, Yanek LR, Becker LC, Linsel-Nitschke P, Lieb W, König IR, Hengstenberg C, Fischer M, Stark K, Reinhard W, Winogradow J, Grassl M, Grosshennig A, Preuss M, Schreiber S, Wichmann HE, Meisinger C, Yee J, Friedlander Y, Do R, Meigs JB, Williams G, Nathan DM, MacRae CA, Qu L, Wilensky RL, Matthai WH, Qasim AN, Hakonarson H, Pichard AD, Kent KM, Satler L, Lindsay JM, Waksman R, Knouff CW, Waterworth DM, Walker MC, Mooser VE, Marrugat J, Lucas G, Subirana I, Sala J, Ramos R, Martinelli N, Olivieri O, Trabetti E, Malerba G, Pignatti PF, Guiducci C, Mirel D, Parkin M, Hirschhorn JN, Asselta R, Duga S, Musunuru K, Daly MJ, Purcell S, Eifert S, Braund PS, Wright BJ, Balmforth AJ, Ball SG, Ouwehand WH, Deloukas P, Scholz M, Cambien F, Hude A, Scheffold T, Salomaa V, Girelli D, Granger CB, Peltonen L, McKeown PP, Altshuler D, Melander O, Devaney JM, Epstein SE, Rader DJ, Elosua R, Engert JC, Anand SS, Hall AS, Ziegler A, O'Donnell CJ, Spertus JA, Siscovick D, Schwartz SM, Becker D, Thorsteinsdottir U, Stefansson K, Schunkert H, Samani NJ, Quertermous T. Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. *J Am Coll Cardiol*. 2010; 56:1552–63. [PubMed: 20933357]
 73. Hallmans G, Agren A, Johansson G, Johansson A, Stegmayr B, Jansson JH, Lindahl B, Rolandsson O, Söderberg S, Nilsson M, Johansson I, Weinehall L. Cardiovascular disease and diabetes in the Northern Sweden Health and Disease Study Cohort - evaluation of risk factors and their interactions. *Scand J Public Health Suppl*. 2003; 61:18–24. [PubMed: 14660243]
 74. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J. Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study. *Ann Intern Med*. 1961; 55:33–50. [PubMed: 13751193]
 75. Hills SA, Balkau B, Coppack SW, Dekker JM, Mari A, Natali A, Walker M, Ferrannini E. The EGIR-RISC STUDY (The European group for the study of insulin resistance: relationship between insulin sensitivity and cardiovascular disease risk): I. Methodology and objectives. *Diabetologia*. 2004; 47:566–70. [PubMed: 14968294]
 76. Lean MEJ, Carraro R, Finer N, Hartvig H, Lindegaard ML, Rössner S, Van Gaal L, Astrup A. NN8022-1807 Investigators. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. *Int J Obes (Lond)*. 2014; 38:689–97. [PubMed: 23942319]
 77. Kelly AS, Rudser KD, Nathan BM, Fox CK, Metzger AM, Coombes BJ, Fitch AK, Bomberg EM, Abuzzahab MJ. The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial. *JAMA Pediatr*. 2013; 167:355–60. [PubMed: 23380890]
 78. Rosenstock J, Klaff LJ, Schwartz S, Northrup J, Holcombe JH, Wilhelm K, Trautmann M. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. *Diabetes Care*. 2010; 33:1173–5. [PubMed: 20332357]
 79. Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. *J Clin Endocrinol Metab*. 2008; 93:2670–8. [PubMed: 18460557]

80. Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Ell P, Soderlund T, Whitton P, Wyse R, Isaacs T, Lees A, Limousin P, Foltynie T. Exenatide and the treatment of patients with Parkinson's disease. *J Clin Invest*. 2013; 123:2730–6. [PubMed: 23728174]
81. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. NN2211-1310 International Study Group. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. *Diabetes Care*. 2004; 27:1335–42. [PubMed: 15161785]
82. Seino Y, Rasmussen MF, Zdravkovic M, Kaku K. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. *Diabetes Res Clin Pract*. 2008; 81:161–8. [PubMed: 18495285]
83. Marre M, Shaw J, Brändle M, Bebakar WMW, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD, Colagiuri S. LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). *Diabet Med*. 2009; 26:268–78. [PubMed: 19317822]
84. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, Matthews DR. LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. *Diabetes Care*. 2009; 32:84–90. [PubMed: 18931095]
85. Forst T, Michelson G, Ratter F, Weber MM, Anders S, Mitry M, Wilhelm B, Pfützner A. Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function. *Diabet Med*. 2012; 29:1115–8. [PubMed: 22288732]
86. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Hale PM, Zdravkovic M, Blonde L. LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). *Diabetes Care*. 2009; 32:1224–30. [PubMed: 19289857]
87. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Simó R. Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. *Diabetologia*. 2009; 52:2046–55. [PubMed: 19688338]
88. Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, Taylor K. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. *Diabetes Care*. 2007; 30:1487–93. [PubMed: 17353504]
89. Kadowaki T, Namba M, Yamamura A, Sowa H, Wolka AM, Brodows RG. Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. *Endocr J*. 2009; 56:415–24. [PubMed: 19194050]
90. Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. *Clin Ther*. 2008; 30:1448–60. [PubMed: 18803987]
91. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. *Diabetes Care*. 2005; 28:1083–91. [PubMed: 15855571]
92. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. *Diabetes Care*. 2005; 28:1092–100. [PubMed: 15855572]
93. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. *Diabetes Care*. 2004; 27:2628–35. [PubMed: 15504997]
94. Apovian CM, Bergenstal RM, Cuddihy RM, Qu Y, Lenox S, Lewis MS, Glass LC. Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. *Am J Med*. 2010; 123:468.e9–17.

95. Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AYM, Hoogwerf BJ, Rosenstock J. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. *Ann Intern Med.* 2011; 154:103–12. [PubMed: 21138825]
96. Gill A, Hoogwerf BJ, Burger J, Bruce S, Macconell L, Yan P, Braun D, Giaconia J, Malone J. Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. *Cardiovasc Diabetol.* 2010; 9:6. [PubMed: 20109208]
97. Liutkus J, Rosas Guzman J, Norwood P, Pop L, Northrup J, Cao D, Trautmann M. A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin. *Diabetes Obes Metab.* 2010; 12:1058–65. [PubMed: 20977576]
98. Zinman B, Hoogwerf BJ, Durán García S, Milton DR, Giaconia JM, Kim DD, Trautmann ME, Brodows RG. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. *Ann Intern Med.* 2007; 146:477–85. [PubMed: 17404349]
99. DeFronzo RA, Triplitt C, Qu Y, Lewis MS, Maggs D, Glass LC. Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. *Diabetes Care.* 2010; 33:951–7. [PubMed: 20107105]
100. Derosa G, Franzetti IG, Querci F, Carbone A, Ciccarelli L, Piccinni MN, Fogari E, Maffioli P. Exenatide plus metformin compared with metformin alone on β -cell function in patients with Type 2 diabetes. *Diabet Med.* 2012; 29:1515–23. [PubMed: 22540883]
101. Derosa G, Franzetti IG, Querci F, Carbone A, Ciccarelli L, Piccinni MN, Fogari E, Maffioli P. Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial. *Pharmacotherapy.* 2013; 33:817–26. [PubMed: 23744726]
102. Gao Y, Yoon KH, Chuang LM, Mohan V, Ning G, Shah S, Jang HC, Wu TJ, Johns D, Northrup J, Brodows R. Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. *Diabetes Res Clin Pract.* 2009; 83:69–76. [PubMed: 19019476]
103. Seino Y, Takami A, Boka G, Niemoeller E, Raccah D. PDY6797 investigators. Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin. *Diabetes Obes Metab.* 2014; 16:739–47. [PubMed: 24524806]
104. Ratner RE, Rosenstock J, Boka G. DRI6012 Study Investigators. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. *Diabet Med.* 2010; 27:1024–32. [PubMed: 20722676]
105. Bolli GB, Munteanu M, Dotsenko S, Niemoeller E, Boka G, Wu Y, Hanefeld M. Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). *Diabet Med.* 2014; 31:176–84. [PubMed: 24117597]
106. Pinget M, Goldenberg R, Niemoeller E, Muehlen-Bartmer I, Guo H, Aronson R. Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). *Diabetes Obes Metab.* 2013; 15:1000–7. [PubMed: 23627775]
107. Riddle MC, Aronson R, Home P, Marre M, Niemoeller E, Miossec P, Ping L, Ye J, Rosenstock J. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). *Diabetes Care.* 2013; 36:2489–96. [PubMed: 23628617]
108. Riddle MC, Forst T, Aronson R, Sauque-Reyna L, Souhami E, Silvestre L, Ping L, Rosenstock J. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). *Diabetes Care.* 2013; 36:2497–503. [PubMed: 23564915]
109. Ahrén B, Leguizamo Dimas A, Miossec P, Saubadu S, Aronson R. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). *Diabetes Care.* 2013; 36:2543–50. [PubMed: 23536584]
110. Rosenstock J, Hanefeld M, Shamanna P, Min KW, Boka G, Miossec P, Zhou T, Muehlen-Bartmer I, Ratner RE. Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic

- levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S). *J Diabetes Complications*. 28:386–92.
111. Seino Y, Min KW, Niemoeller E, Takami A. EFC10887 GETGOAL-L Asia Study Investigators. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). *Diabetes Obes Metab*. 2012; 14:910–7. [PubMed: 22564709]
 112. Yu Pan C, Han P, Liu X, Yan S, Feng P, Zhou Z, Lv X, Tian H, Jin Kui Y, Su B, Shang S, Niemoeller E. Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia). *Diabetes Metab Res Rev*. 2014; 30:726–35. [PubMed: 24639432]
 113. Fonseca VA, Alvarado-Ruiz R, Raccach D, Boka G, Miossec P, Gerich JE. EFC6018 GetGoal-Mono Study Investigators. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). *Diabetes Care*. 2012; 35:1225–31. [PubMed: 22432104]
 114. Morris AP, Voight BF, Teslovich TM, Ferreira T, Segrè AV, Steinthorsdottir V, Strawbridge RJ, Khan H, Grallert H, Mahajan A, Prokopenko I, Kang HM, Dina C, Esko T, Fraser RM, Kanoni S, Kumar A, Lagou V, Langenberg C, Luan J, Lindgren CM, Müller-Nurasyid M, Pechlivanis S, Rayner NW, Scott LJ, Wiltshire S, Yengo L, Kinnunen L, Rossin EJ, Raychaudhuri S, Johnson AD, Dimas AS, Loos RJF, Vedantam S, Chen H, Florez JC, Fox C, Liu CT, Rybin D, Couper DJ, Kao WHL, Li M, Cornelis MC, Kraft P, Sun Q, van Dam RM, Stringham HM, Chines PS, Fischer K, Fontanillas P, Holmen OL, Hunt SE, Jackson AU, Kong A, Lawrence R, Meyer J, Perry JRB, Platou CGP, Potter S, Rehnberg E, Robertson N, Sivapalaratnam S, Stan áková A, Stirrups K, Thorleifsson G, Tikkanen E, Wood AR, Almgren P, Atalay M, Benediktsson R, Bonnycastle LL, Burt N, Carey J, Charpentier G, Crenshaw AT, Doney ASF, Dorkhan M, Edkins S, Emilsson V, Eury E, Forsen T, Gertow K, Gigante B, Grant GB, Groves CJ, Guiducci C, Herder C, Hreidarsson AB, Hui J, James A, Jonsson A, Rathmann W, Klopp N, Kravic J, Krjutškov K, Langford C, Leander K, Lindholm E, Lobbens S, Männistö S, Mirza G, Mühleisen TW, Musk B, Parkin M, Rallidis L, Saramies J, Sennblad B, Shah S, Sigurðsson G, Silveira A, Steinbach G, Thorand B, Trakalo J, Veglia F, Wennyauer R, Winckler W, Zabaneh D, Campbell H, van Duijn C, Uitterlinden AG, Hofman A, Sijbrands E, Abecasis GR, Owen KR, Zeggini E, Trip MD, Forouhi NG, Syvänen AC, Eriksson JG, Peltonen L, Nöthen MM, Balkau B, Palmer CNa, Lyssenko V, Tuomi T, Isomaa B, Hunter DJ, Qi L, Shuldiner AR, Roden M, Barroso I, Wilsgaard T, Beilby J, Hovingh K, Price JF, Wilson JF, Rauramaa R, Lakka Ta, Lind L, Dedoussis G, Njølstad I, Pedersen NL, Khaw KT, Wareham NJ, Keinanen-Kiukkaanniemi SM, Saaristo TE, Korpi-Hyövälti E, Saltevo J, Laakso M, Kuusisto J, Metspalu A, Collins FS, Mohlke KL, Bergman RN, Tuomilehto J, Boehm BO, Gieger C, Hveem K, Cauchi S, Froguel P, Baldassarre D, Tremoli E, Humphries SE, Saleheen D, Danesh J, Ingelsson E, Ripatti S, Salomaa V, Erbel R, Jöckel KHJ, Moebus S, Peters A, Illig T, de Faire U, Hamsten A, Donnelly PJ, Frayling TM, Hattersley AT, Boerwinkle E, Melander O, Kathiresan S, Nilsson PM, Deloukas P, Thorsteinsdottir U, Groop LC, Stefansson K, Hu F, Pankow JS, Dupuis J, Meigs JB, Altshuler D, Boehnke M, Mc Carthy MI. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. *Nat Genet*. 2012; 44:981–90. [PubMed: 22885922]
 115. Lorenz M, Pfeiffer C, Steinsträsser A, Becker RHA, Rütten H, Ruus P, Horowitz M. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia. *Regul Pept*. 2013; 185:1–8. [PubMed: 23665027]




Figure 1. Overall study design, participating studies, and consortia

Discovery analyses were performed using targeted exome sequencing of variation in six genes tested for association with seven traits. Variants were taken forward to follow-up by targeted genotyping. Additional *in silico* results were obtained using available association results. Combined results were obtained by fixed-effect meta-analysis of estimates from linear or logistic regression, as appropriate. Based on the 1331 statistical tests performed in discovery analyses, $p < 3.8 \times 10^{-5}$ was used as the threshold for statistical significance. In targeted genotyping, (g) refers to studies that were directly genotyped for relevant markers, whereas (i) indicates those in which relevant variants were captured by imputation.




Figure 2. Association of *GLP1R* variant (rs10305492) with glycaemic traits
(A) Genetic variant association with glycaemic traits. Data are standard deviations per minor allele at rs10305492. Fasting glucose results are from the combined analysis (Table 1). Individual studies contributing to the associations for fasting insulin and 2-h glucose are in table S4. All results reflect point estimates and 95% confidence intervals (CI) from a fixed-effect meta-analysis of linear regression estimates. (B) Effect size of the *GLP1R* variant (in red) and loci previously reported to be associated with fasting glucose. Effect sizes are reported from discovery analyses of available MAGIC results (50), and from the combined estimate for the *GLP1R* variant in (A).




Figure 3. Comparison of *GLP1R* variant (rs10305492) associations with effects observed in clinical trials of GLP1R agonists in non-diabetic individuals and in individuals with T2D

Genetic associations are all scaled to match the effects of GLP1R-agonists on fasting glucose (i.e. per 3.3 copies of the minor (A) allele). Genetic variant results are beta estimates and 95% confidence intervals from fixed effect meta-analysis of linear regression results

Trial results are estimates from fixed-effect meta-analyses of standardised mean differences between treatment and comparison groups of the individual trials listed in table S3. *Trials reported effects on body mass, whereas genetic associations were only available for BMI.




Figure 4. Association of *GLPIR* variant (rs10305492) with disease outcomes
 Association with disease outcomes are reported per-minor allele at rs10305492. Data show odds ratios and 95% confidence intervals from logistic regression models.

Table 1
Discovery, follow-up, and combined results for variants taken forward to follow-up

Seven variants in six genes reached $p < 0.001$ (or $p < 0.05$ in target of interest to GSK) in sequence-based discovery analyses (Fig. 1) and were taken forward to follow-up in additional samples, by targeted genotyping and by *in silico* lookup from existing consortia. Data and P values are from fixed effect meta-analysis of linear regression for quantitative traits or logistic regression for binary disease status.

Gene	Variant	Chr	Position (NCBI b37 genome alignment)	Consequence	Trait	Effect allele	Other allele	MAF	Stage	Study	n (case/control for binary trait)	Beta (Odds ratio for binary trait)	se [CI for OR]	P -value
<i>GLPIR</i>	rs10305492	6	39046794	A316T	Fasting glucose	A	G	0.015	Discovery	Sequenced CoLaus*	1869	-0.28	0.14	0.04
									Targeted follow-up	Additional CoLaus, ELX, Fenland, LOLIPOP, GEMS	18,937	-0.13	0.04	1.5×10^{-3}
									In silico follow-up	MAGIC (29)	20,077	-0.16	0.03	1.1×10^{-2}
									Combined		40,883	-0.15	0.02	2.6×10^{-10}
<i>DPP4</i>	rs56179129	2	162890142	V266I	Fasting glucose	T	C	0.008	Discovery	GEMS	1416	0.61	0.21	3.6×10^{-3}
									Targeted follow-up	CoLaus, ELX, LOLIPOP	12934	0.00	0.07	0.95
									In silico follow-up	CHARGE Exome chip (18)	49838	0.00	0.03	0.16
									Combined		64188	0.01	0.03	0.71
<i>SLC5A1</i>	rs200410750	22	32439209	5' UTR	Fasting Glucose	T	C	0.001	Discovery	Sequenced and imputed CoLaus	5210	1.44	0.33	1.7×10^{-5}
									Targeted follow-up	ELX, Fenland, LOLIPOP	12707	-0.16	0.27	0.56
									In silico follow-up	n/a				NA
									Combined		18059	0.51	0.19	0.01
<i>CNR2</i>	rs4649124	1	24201357	Synonymous	2 hour glucose	A	G	0.420	Discovery	Sequenced and imputed CoLaus	505	0.18	0.06	0.01
									Targeted follow-up	ELX, Fenland	6377	0.00	0.02	0.95
									In silico follow-up	MAGIC (proxy: rs10917431)(49)	15234	-0.01	0.01	0.49
									Combined		22106	0.00	0.01	0.88
<i>CNR2</i>	rs2229579	1	24201162	H316Y	T2D	T	C	0.110	Discovery	Sequenced and imputed CoLaus	385/5241	0.73	[0.55, 0.97]	0.03
									Targeted follow-up	ADDITION-ELY, NDS, LOLIPOP, GenOA	7141/27096	1.06	[0.99, 1.14]	0.07
									In silico follow-up	CHARGE Exome chip (18)	9524/60718	0.96	[0.90, 1.01]	0.10
									Combined		17047/93225	0.99	[0.95, 1.04]	0.67
<i>HTR2C</i>	rs56372597	X	113951968	Intronic	BMI	A	G	0.150	Discovery	BMI	10798	0.05	0.02	2.1×10^{-3}
									Targeted follow-up	Additional CoLaus, ELX, EPIC, Fenland, LOLIPOP	36983	0.00	0.01	0.92

Gene	Variant	Chr	Position (NCBI b37 genome alignment)	Consequence	Trait	Effect allele	Other allele	MAF	Stage	Study	<i>n</i> (case/control for binary trait)	Beta (Odds ratio for binary trait)	se [CI for OR]	<i>P</i> -value
In silico follow-up														
Combined														
<i>MCHRI</i>	rs117372135	22	41075523	T25M	BMI	T	C	0.002	Discovery	BMI	10952	0.62	0.15	4.5×10 ⁻⁵
									Targeted follow-up	Additional CoLaus, ELY, EPIC, Fenland, LOLIPOP	37240	0.08	0.10	0.40
									In silico follow-up	CHARGE adiposity Exome chip working group	68978	-0.04	0.07	0.59
									Combined		117170	0.08	0.05	0.13
									n/a					
0.13														
0.01														

* Analyzed in sequenced CoLaus participants only owing to low imputation quality ($R^2 < 0.5$) in additional CoLaus participants at the discovery stage. #Not analyzed in GEMS due to low number of carriers (< 5 minor alleles)